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ABSTRACT OF THE DISSERTATION
The Role of the Circadian Clock Protein Rev-erbα in Neuroinflammation & Synaptic Health
by Percy Griffin
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Cell Biology
Washington University in St. Louis 2020
Professor Joseph Dougherty, Chair

Circadian rhythms are cycles of physiological activity that are conserved across all of
life’s taxa – ranging from cyanobacteria to humans - due to their importance. They are conserved
to allow organisms to maximize their capacity to obtain resources in their environment. In
mammals, light and dark input into the retina is the strongest synchronizer of circadian rhythms.
On the molecular level, this tightly regulated transcriptional-translational feedback loop is
orchestrated by proteins with cyclical expression. The loss of these proteins has functional
consequences on human health and diseases.
Recently, associations have been made between circadian proteins and a host of
pathological conditions including cancer, diabetes, obesity, inflammation, and
neurodegeneration. In 2013, Dr. Erik Musiek established a link between the core circadian clock
protein BMAL1 and neurodegeneration as well as redox homeostasis (Musiek et al., 2013). Since
then, other work has also shown circadian dysfunction to be a prominent symptom of
Alzheimer’s disease. In establishing the role of BMAL1 in neurodegeneration, Dr. Musiek also
noted a stark age-dependent increase in astrocyte and microglial activation. These glial cells are
essential for brain homeostasis and play roles in central nervous disease pathogenesis.

xiv

To further understand the role of the circadian clock in regulating glial activation, we
investigated the circadian protein REV-ERBα. Canonically, BMAL1 drives the transcription of a
number of genes. One of those genes is Nr1d1, which codes for REV-ERBα - a dedicated
transcriptional repressor. Although REV-ERBα was not initially described in the core clock
machinery, this protein can also inhibit production of BMAL1 by binding to consensus
sequences. Since REV-ERBα is downstream of BMAL1, we asked the question, does REVERBα play a role in regulating glial activation and if so, what are the consequences to neuronal
health?
In the periphery, REV-ERBα had already been shown to play a role in regulating
macrophage activation (Gibbs et al., 2012). Therefore, we investigated microglia first for a
functional role of REV-ERBα. Deletion of REV-ERBα induced spontaneous microglial
activation in areas of the mouse brain such as the hippocampus. This spontaneous activation
abrogated time-of-day oscillation in microglial activation. In culture, isolated microglial lacking
REV-ERBα also exhibited pro-inflammatory phenotypes and increased basal NFκB signaling.
We also found through Chromatin immunoprecipitation (ChIP) that REV-ERBα physically
interacted with several NFκB genes in microglia. Primary microglia lacking REV-ERBα also
exhibited an exacerbated response to the inflammogen lipopolysaccharide (LPS).
Within the brain parenchyma, microglia and astrocytes interact closely. Activated
microglia can in turn induce astrocyte activation (Liddelow et al., 2017). In the brain, knocking
out REV-ERBα also resulted in astrocyte activation. However, in contrast to the microglia,
primary astrocytes isolated from REV-ERBα knockout mice did not show a basal activated
phenotype in culture but did respond to an LPS challenge. Since REV-ERBα is a ligand sensitive
nuclear receptor, it can be targeted by small molecules. One such molecule is SR9009, which
xv

was synthesized by our collaborators in the Burris lab (Solt et al., 2012). Application of this drug
reduced LPS induced neuroinflammation in mice and IL-1β release from primary microglia, but
was ineffective in cells lacking REV-ERBα.
Activated glia can influence neuronal health in the brain (Andreasson et al., 2016).
Accordingly, primary neurons grown in conditioned media from REV-ERBα deficient primary
glial cultures were more susceptible to oxidative damage. In the CA3 region of the hippocampus,
we also noted a striking reduction in synaptic volume in the REV-ERBα knockout mice.
Notably, presynaptic terminals showed a decrease in immunoreactivity by multiple methods.
Synapses can be tagged for microglia-mediated removal by complement molecules (Stevens et
al., 2007). In both BMAL1 knockout and REV-ERBα knockout mice, we noted increases in
complement gene expression as well as complement protein expression in astrocytes and
microglia. We then observed striking increases in microglia-mediated synaptic pruning in the
REV-ERBα knockout mice. Interestingly, REV-ERBα deletion also abrogated oscillations in
microglia-mediated synaptic pruning. Since synaptic connections are used for communication
between brain regions, we also assessed the overall functional brain connectivity. In REV-ERBα
knockout mice, we observed decreases in resting state functional connectivity in brain areas
associated with neurodegeneration. Overall, the work here highlights a novel role for a circadian
protein in various facets of glial and neuronal health. It also establishes a pharmacologically
accessible link between the circadian clock and neuroinflammation, which can potentially be
leveraged to treat neurodegenerative disease

xvi

Chapter 1: Introduction
1.1 Brief Overview
Often in science, we are concerned with understanding the what and the how. In this
thesis, we consider a third question – when? This question is asked in one of the least understood
organs of the body – the brain. I explore how the circadian clock affects glial cells in the brain.
While microglia are the primary focus of this dissertation, astrocytes are also affected
significantly by clock dysfunction. A basic understanding of the circadian clock is necessary to
appreciate the body of work in this dissertation.

1.2 Discovery of the Molecular Circadian Clock
The 24-hour (h) day-night cycle exerts strong, predictable behavioral pressures on all
organisms on Earth. It is therefore unsurprising that most terrestrial species have evolved
molecular machinery, which allows them to tailor their physiology to the time-of-day (Vitaterna
et al., 2001). The term Circadian itself comes from the Latin circa diem, which means ‘about a
day’(Partch et al., 2014). Although circadian rhythms had been previously observed in nature,
the first description of their programmed nature came from Jean Jacques d’Ortous de Marian’s
observations of the mimosa plant in 1729 (Roenneberg and Merrow, 2005). However, the idea of
an internal clock really took hold in the 20th century. In the early 1970’s Ronald Konopka and
Seymour Benzer were the first to describe clock mutants in fruit flies that altered physiological
timing(Konopka and Benzer, 1971). This established the genetic basis for cycles in physiology.
Insights into the molecular basis of the clock were not elucidated until 1984 by Michael Rosbash
and Jeffrey Hall (Reddy et al., 1984). In this seminal paper, they described the protein PER in
Drosophila melanogaster as one of the crucial genes for the control of biological rhythms (Reddy
et al., 1984). Like other factors that regulate the clock, PER has to find its way into the nucleus
1

to bind to genomic elements. This regulatory mechanism was determined by Michael Hall and
colleagues in 1994 to be based on the phosphorylation status of the PER protein (Edery et al.,
1994).
Around the same time, the Takahashi lab discovered the gene Clock, which possessed
mutations that could lengthen the circadian period and abolish rhythmicity (Vitaterna et al.,
1994). In 1999 the Yasui group discovered the necessity of mammalian cryptochrome proteins
(CRY1 and CRY2) in maintaining circadian behavior (van der Horst et al., 1999). Together with
the protein BMAL1 (which will be reviewed in section 1.1), these proteins form the core clock
proteins. A schematic of the core circadian clock proteins/genes in addition to Nr1d1/Nr1d2 and
the regulatory interactions is depicted in Figure 1.1. Briefly, the BMAL1 and CLOCK
heterodimerize to drive the transcription of a host of genes including the clock-controlled genes
as well as their own repressors (Lowrey and Takahashi, 2011). These repressors include the PER
and CRY family of proteins as well as the REV-ERBS (α/β). PER and CRY then heterodimerize
and compete for the same consensus sequences (E-box motifs) that BMAL1/CLOCK
heterodimers bind to (Dunlap, 1999). The REV-ERBs compete with the ROR proteins, which
drive BMAL1 transcription, for RORE sites (Papazyan et al., 2016), thus effectively suppressing
Arntl expression.

2

Figure 1.1 A simplified schematic of the core clock proteins and their regulatory interactions.
This scheme shows a heterodimer of BMAL1/CLOCK driving the transcription of its repressors as
well as other clock-controlled genes.

3

1.3 BMAL1 Discovery & Clock Function
The BMAL1/CLOCK heterodimer constitutes the positive limb of the circadian feedback
loop. It drives the transcription of thousands of clock-controlled genes by binding to DNA
elements known as E-boxes (5’-CACGTG-3’) or E’-boxes (5’-CACGTT-3’) (Buhr and
Takahashi, 2013). Although both CLOCK and BMAL1 have basic helix-loop-helix (bHLH) as
well as Per-Arnt-Sim (PAS) domains to facilitate DNA binding (Lowrey and Takahashi, 2000),
BMAL1 is the only single protein deletion that abolishes behavioral circadian rhythms in darkdark conditions (Bunger et al., 2000). As such, BMAL1 has been extensively studied for its roles
in various facets of circadian biology. However, at the time of its discovery, BMAL1’s role in
the clock was not known.
BMAL1 or MOP3 was identified as part of a screen for novel bHLH-PAS proteins that
interact with the Aryl hydrocarbon receptor (AHR) or Ah receptor nuclear translocator (ARNT)
(Hogenesch et al., 1997). The initial purpose of this screen was to comprehend the mechanism of
2,3,7,8-tetrachlorodibenzo-p-dioxin toxicity (Hogenesch et al., 1997). In the screen, Hogenesch
and colleagues identified MOPs 1-5, with MOP3 forming strong associations with heat shock
protein-90 (HSP90) (Hogenesch et al., 1997). Shortly after discovering MOP3, Hogenesch and
colleagues demonstrated that it bound to hypoxia inducible factor 1α (HIF1α) and CLOCK to
drive gene transcription (Hogenesch et al., 1998). Similar to the BMAL1/CLOCK heterodimer,
HIF proteins also bind to E-box like motifs in the genome (Kaelin and Ratcliffe, 2008). These
observations implicated a potential function of MOP3 in the molecular circadian clock.
However, Bunger and colleagues definitively established the role of BMAL1 in the
circadian clock. In their study, they found that Mop3-/- mice displayed arrhythmic behavior
under free running conditions (Bunger et al., 2000). These results are shown in Figure 1.2.
Interestingly, deletion of MOP3 also led to reduced overall activity levels as well as gene
expression in the liver and suprachiasmatic nucleus(Bunger et al., 2000). Critically, MOP3 is not
4

redundant, because its homolog, MOP9 (BMAL2), was not sufficient to restore circadian activity
(Bunger et al., 2000). Overall, these experiments establish the role of BMAL1 as a nonredundant, indispensable component of the molecular circadian clock machinery. The
BMAL1/CLOCK heterodimer drives the transcription of the Nr1d1/Nr1d2 family of genes,
which code for REV-ERBα/REV-ERBβ. In this thesis, I will primarily be focusing on REVERBα.

5

Figure 1.2 Mouse Wheel Running Activity showing in Wild-Type (WT) and Mop3 -/- mice.
Representative double plotted activity records of individual WT mice (A and B) and Mop3 -/- mice (C
and D). The bar above shows the activity shows the light-dark cycle. Mice were house in a light dark
(LD) cycle for 14 days and then transferred to constant darkness (DD). (Bunger et al., 2000)

6

1.4 REV-ERBα Discovery & Clock Function
The initial description of the gene products from which REV-ERBα was translated came
from the Yamamoto group in 1988 (Miyajima et al., 1988). In their paper, they described the
(erbA-related genes) ear-2 and ear-3 with gene products that gave rise to proteins with a similar
primary structure to receptors for steroid hormones or thyroid hormone (T3) (Miyajima et al.,
1988). After the initial discovery, the same group found 2 erbA proteins that could be transcribed
from the opposite DNA strand of the same genetic locus in human cells(Miyajima et al., 1989).
Around the same time, Lazar and colleagues characterized a 56 kilodalton (kDa) protein, which
they called Rev-ErbAα, from a rat GH3 cell library (Lazar et al., 1989). This protein was found
to be a new member of the thyroid/steroid hormone receptor super family and was expressed in
many tissues including the heart, brain, liver, kidney, brown fat and skeletal muscle (Lazar et al.,
1989). The highest expression was seen in the brain, brown fat and skeletal muscle (Lazar et al.,
1989).
REV-ERBα gets its name because it is transcribed from the ‘reverse strand of r-erbAα’
(Kojetin and Burris, 2014). At the time of its discovery, the Rev-ErbAα/r-erbAα locus was the
first example of structurally related proteins being encoded by overlapping transcriptional units
in eukaryotes (Lazar et al., 1989). When REV-ERBα was discovered, the endogenous ligand as
well as its function were unknown, but highly speculated. Although REV-ERBα was a part of
the steroid/thyroid hormone receptor superfamily, it did not bind to thyroid hormone (Lazar et
al., 1990). REV-ERBα was also found to be conserved between rats and humans (Lazar et al.,
1990) suggesting an important function in mammalian cells. REV-ERBα is an orphan receptor
similar to the TR/retinoic acid receptor (RAR) subgroup of nuclear receptors, which all bind to
the genome using a DNA binding domain (DBD) (Lazar et al., 1989). These studies established
REV-ERBα as a ligand sensitive, nuclear receptor protein with putative transcription regulatory
activity.
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Initial insights into the ligand for REV-ERBα came from fruit fly studies where they
described heme as an activating agent for the drosophila ortholog E75 (Reinking et al., 2005).
Shortly thereafter, others showed that binding of physiological heme to REV-ERBα repressed
BMAL1 and recruited NCoR (Raghuram et al., 2007). Structural studies also demonstrated that
the heme binding pocket was located in the same region as other nuclear receptors (Pardee et al.,
2009). A space filling model of REV-ERBα bound to NCoR is shown in Figure 1.3. These
discoveries suggested potential REV-ERBα modulation by synthetic ligands. Consequently, the
first synthetic ligand for REV-ERBα (named GSK4112) was identified using a fluorescence
resonance energy transfer (FRET) biochemical screen (Golombek et al., 2004). Since then, more
bioavailable REV-ERB agonists such as SR9009 and SR9011 (Solt et al., 2012) have been
developed. However, only one antagonist (SR8278) is currently being used extensively (Kojetin
et al., 2011). The interest in REV-ERB activity modulation is partially due to its regulation of
metabolism and circadian rhythms.
REV-ERBα deletion increases triglycerides, very low-density lipoprotein, apoCIII levels
and reduces body weight (Burris, 2008). Furthermore, REV-ERBα regulates the expression of
genes encoding phosphoenolpyruvate carboxykinase (PCK) and glucose-6-phostphatase (G6PC)
(Yin et al., 2007). Generally, nuclear receptors serve to couple circadian clocks to metabolic
output (Yang et al., 2006) and REV-ERBα plays a critical role in that coupling. In its circadian
role, REV-ERBα regulates the transcription of BMAL1 (Preitner et al., 2002) as an auxiliary
negative limb protein of the clock. The primary means of circadian regulation by REV-ERBα is
through its binding to genomic elements. Also, PER2 from the core negative limb of the clock
regulates the transcription of REV-ERBα (Schmutz et al., 2010). Unlike BMAL1, deletion of
REV-ERBα alone does not result in behavioral arrhythmicity (Cho et al., 2012a). Both REVERBα and its homology REV-ERBβ need to be deleted to abrogate behavioral circadian rhythms
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(Cho et al., 2012a). Overall REV-ERBα is a stabilizing arm of the clock, but the details of how
it regulates gene expression in various tissues is discussed in the next section.
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Figure 1.3: Space-Filling Models of REV-ERBα
α Bound to its Co-Repressor NCoR.
(Kojetin and Burris, 2014). Co-crystal structures of REV-ERBα and NCor
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1.5 Mechanisms of Transcriptional Regulation by REV-ERBα &
BMAL1
Like other member of the steroid/thyroid hormone receptor superfamily, REV-ERBα has
a DNA binding domain (DBD) that contains two zinc fingers of the Cys4 type (Evans, 1988).
This hinted at a putative regulatory role on the transcriptional level. Shortly after its discovery,
REV-ERBα was found to bind to a unique 5-base pair (bp) A/T rich sequence adjacent to an
AGGTCA half site (Harding and Lazar, 1993) – initially referred to as a Rev monomer site
(Harding and Lazar, 1995) and later renamed to RORE sites (Giguère et al., 1995). However, it
was later shown that in its repressive capacity, REV-ERBα bound as a homodimer to two Rev
monomer sites arranged as direct repeats with the AGCTCA motif separated by 2 bp -known as a
Rev-DR2 site (Harding and Lazar, 1995).
Typically, Nuclear Receptors (NRs) bind co-activators or corepressors to either drive or
repress gene transcription (McKenna and O'Malley, 2002). REV-ERBα binds via an atypical
interaction of 2 regions within the N-terminal region separated by 200 amino acids to NCoR
(Zamir et al., 1996). This binding usually occurs after REV-ERBα associates with the target
DNA elements (Zamir et al., 1997). The complex then associates with Histone Deacetylase 3
(HDAC3), which contains the catalytic element required for the repressive activities (Yin and
Lazar, 2005). In the mammalian nucleus, DNA is organized into chromatin, which is made up of
histone proteins (Soshnev et al., 2016). Therefore, histone modifications, which modulate the
accessibility of transcriptional elements in the genome, are crucial for gene expression regulation
(Soshnev et al., 2016). Acetylation of the 9th and 27th lysines of Histone 3 (H3K9ac and
H3K27ac) are the markers of active promoters and enhancers respectively (Barnes et al., 2019).
Histone Acetyltransferases (HATs) acetylate histones and Histone Deacetylases (HDACs)
removes those protein modifications (Eberharter and Becker, 2002). HDAC3, which is recruited
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to the REV-ERBα/NCoR complex, deacetylates histones (Karagianni and Wong, 2007) near the
RORE sites. At these sites, REV-ERBα competes with RORα for binding (Forman et al., 1994).
During the day circadian day (between ZT 6-12), REV-ERBα expression peaks and the complex
represses gene expression at RORE sites (Papazyan et al., 2016). At night (ZT 18-24), REVERBα expression is low, and this allows RORα to bind to RORE sites and drive the
transcription of numerous genes by acetylating histones (Papazyan et al., 2016). This relationship
is depicted in Figure 1.4. One of these genes is Arntl, which codes for BMAL1 protein
(Guillaumond et al., 2005).
Like REV-ERBα, BMAL1 binds to the DNA and regulates gene transcription
(Takahashi, 2017). The BMAL1/CLOCK heterodimer drives the transcription of genes by
binding to E-box motifs (CANNTG) (Rey et al., 2011). Early in the activation phase, CLOCK’s
intrinsic HAT activity helps initiate essential acetylation events for gene transcription (Doi et al.,
2006). Over time, the BMAL1/CLOCK heterodimer binds to p300 and CBP proteins that have
HAT activity to further loosen up chromatin to enhance gene transcription (Lee et al., 2010). In
addition, the complexes also include Thyroid hormone receptor associated protein-150 (TRAP150), which also promotes gene transcription (Lande-Diner et al., 2013). The BMAL1/CLOCK
heterodimer complex contains other proteins that are capable of chromatin modification. The
mixed lineage leukemia 1 (MLL1) protein is also present in these complexes and can methylate
lysine 4 on histone 3 – a mark that promotes gene expression (Katada and Sassone-Corsi, 2010).
Other clock associated proteins that have been shown to co-precipitate with the BMAL1/CLOCK
complex include the Mediator complex, JARID1A, LSD1, DDB1-CUL4 complex and WDR76
(Papazyan et al., 2016). Under basal physiological conditions REV-ERBα represses gene
expression and the BMAL1/CLOCK heterodimer promotes it. These processes are essential to
the circadian clock and proper timing of physiological activity. The myriad disease processes
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that arise from circadian clock disruption only demonstrate the importance of the clock in human
health.
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Figure 1.4 Schematic showing the competition for RORE Sites by REV-ERBα
α and RORα
α
as well as the associated regulatory proteins (Papazyan et al., 2016). Top: Monomeric binding
of RORα to RORE sites in the night, the HAT containing activating complex as well as the
acetylated histones for gene transcription. Bottom: Dimeric binding of REV-ERBα to RORE
sites in the day, the HDAC containing complex as well as the deacetylated histones to repression
gene transcription.
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1.6 Rev-erbα in Immunity & Disease
Considering REV-ERBα regulates gene transcription in many tissues, it is unsurprising
that the protein is associated with numerous disease states. A summary of the cell type specific
functions of REV-ERBα is shown in figure 1.5. These disease states include cancer (Sulli et al.,
2018), atherosclerosis (Sitaula et al., 2015), obesity (Ruano et al., 2014), diabetes/metabolic
disease (Bugge et al., 2012), autoimmunity (Kojetin and Burris, 2014) and Alzheimer’s Disease
(Lee et al., 2020a). A recurring theme in the aforementioned diseases is the immune system.
Recent evidence has established the circadian timing as an essential aspect of immune
system function (Arjona et al., 2012). Although other clock components, such as BMAL1, play
roles in circadian regulation of immunity, I will focus only on the roles of REV-ERBα. In 2012,
Gibbs et al demonstrated REV-ERBα-dependent regulation of inflammatory cytokines including
il6, cxcl11, ccl2, cxcl6, il9, il12 and ccl5 (Gibbs et al., 2012). Furthermore, loss of REV-ERBα
protein abrogated rhythmicity in lipopolysaccharide (LPS) induced IL-6 release and locked
cytokine levels in an elevated state (Gibbs et al., 2012). REV-ERBα also regulates diurnal
oscillation of NLRP3 expression and secretion of cytokines, such as IL-1β and IL8, that are
matured in the inflammasome (Pourcet et al., 2018b). In the NFκB signaling cascade, REVERBα also regulates P65 (Hergenhan et al., 2020). In the periphery, most of the initial studies
regarding REV-ERBα and the immune system were done in macrophages. This drove our
interest in central nervous system macrophages.
REV-ERBα has also been shown to directly bind and repress the Nfil3 promoter (Yu et
al., 2013). This has profound effects on the differentiation of T helper 17 (TH17) cells, which
have been implicated in autoimmune diseases such as multiple sclerosis (Amir et al., 2018). This
suggests roles for REV-ERBα in other immune cell types apart from macrophages. Recently,
REV-ERBα was also shown to modulate chromatin looping, which has implications for gene
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expression (Kim et al., 2018). REV-ERBα also represses the transcription of enhancer-derived
RNAs (eRNAs)in macrophages (Lam et al., 2013). Future studies could unearth REV-ERBαmediated regulation of immunity in other cell types of the adaptive immune system. Chromatin
looping and eRNA regulation are new and therefore the involvement of REV-ERBα in these
regulatory mechanisms has exciting implications. While this section mostly discusses REVERB’s DBD-mediated mechanisms of control, other DBD independent modes of regulation have
been described. REV-ERBα also has tissue-specific binding sites that are independent of the
DBD (Butler and Burris, 2015). DBD-independent tethering of REV-ERBα have been shown to
be the dominant mode of binding (Butler and Burris, 2015). This mechanism provides modular
flexibility in a cell-specific manner based on differential expression of anchor proteins (Butler
and Burris, 2015). However, in this thesis we focus primarily on REV-ERBα in the immune
cells of the central nervous system.
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Figure 1.5 Tissue specific functions of REV-ERBα
α (Illustrated with information from (Everett and
Lazar, 2014). Briefly, REV-ERBα has been shown to regulate processes in the liver, fat tissues, pancreas,
muscle, brain and macrophages. These effects arise from the transcriptional regulation by REV-ERBα.
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1.7 Overview of Glia
1.7a Microglia
Microglia are the tissue resident macrophages of the central nervous system (CNS) and
regulate process ranging from neuronal development to disease response (Ginhoux and
Guilliams, 2016). They were first described by Pío del Río Hortega in 1913 when he made
drawings of brain tissue after staining with the Golgi-Hortega method (Pérez-Cerdá et al., 2015).
Even for the time, his drawings were incredibly accurate – the microglia he depicted were similar
to those taken using a confocal microscope over 100 years later (Figure 1.6). Since their
discovery, microglia have become the focus of myriad CNS disorders. Recently, the tools
available to study these cells have expanded – allowing us to gain deeper insights on their
functions in homeostasis and disease.
Although microglia and peripheral macrophages both arise from embryonic yolk sac
precursors (Ginhoux et al., 2010), microglial identity is established by a combination of TGF-β
signaling (Butovsky et al., 2014) and brain environment (Gosselin et al., 2014). During
development, erythromyeloid precursors give rise to yolk macrophages that migrate into the
neuroectoderm on day 9.5 (Nayak et al., 2014). Phenotypically, microglia under basal conditions
appear ramified, as seen in Figure 1.6. Even under basal conditions, microglia are very dynamic
and consistently sample the brain microenvironment by extending processes (Nimmerjahn et al.,
2005). Microglia depend on Adenosine Triphosphate (ATP), gap junction proteins or connexins
to facilitate their surveillance functions (Davalos et al., 2005). The purinergic receptor P2Y12 is
the ATP sensing machinery on the microglial cell surface used for chemotaxis (Haynes et al.,
2006). Living cells have nucleotides sequestered away in the intracellular space by intact
membranes. In the event of apoptosis (or other forms of cell death), nucleotides are released into
the extracellular space due to compromised membranes (Elmore, 2007). This makes extracellular
nucleotides an excellent chemoattractant for microglia. Additionally, microglia use the
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fractalkine receptor CX3 chemokine receptor 1 (CX3CR1) to mediate surveillance by binding to
and responding the chemotactic cytokine CX3CL1 on neurons (Limatola and Ransohoff, 2014).
As part of the innate immune system, microglia initiate their response by host recognition
of pathogen-associated molecular patterns (PAMPs) – that are expressed on microbial pathogens
– or danger-associated molecular patterns (DAMPs) – that are produced by host cells (Bryant
and Fitzgerald, 2009). The physiological response of microglia (and other glia) to infections,
disease and injuries by releasing proinflammatory molecules is termed neuroinflammation
(Hanisch and Kettenmann, 2007). Generally, acute neuroinflammation in response to an immune
challenge is required for normal brain homeostasis (Badie and Schartner, 2000). However,
chronic neuroinflammation is damaging to neurons and can be associated with the pathogenesis
of many brain diseases (Eikelenboom et al., 2006). Microglia possess a wide array of cell surface
receptors that mediate their responses to changes in the brain parenchyma. One of these changes
is synaptic pruning, which we examine extensively in this thesis.
As early as 1996, it was hypothesized that brain synaptic architecture was dynamic and
regulated in an activity dependent manner (Katz and Shatz, 1996). Eventually, it was shown that
microglia dynamically interact with synapses (such as hippocampal synapses) via the
CX3CR1receptor (Paolicelli et al., 2011). Furthermore, the Stevens lab showed that microglia
prune synapses in the post-natal retinogeniculate system (Schafer et al., 2012). This process is
dependent on the classical complement cascade (Schafer et al., 2012). In the periphery, the
complement cascade has been extensive studied as one of the immediate responses to an immune
challenge. However, the functions of this cascade are less established in the brain parenchyma.
Schafer et al demonstrated that synapses labeled with complement component 3 (C3) and
complement component 1q (C1q) are targeted for phagocytosis by microglia (Schafer et al.,
2012). Microglia are the primary source of C1q in the brain under basal conditions (Fonseca et
al., 2017). In disease states, C1q localizes to neurons (Fonseca et al., 2004). It is believed that
C1q begins the process of pruning and the complement receptor 3 (CR3)/C3 pair mediate
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microglial phagocytosis (Stevens et al., 2007). The full details of the mechanism are being
actively investigated by other labs.
Since its discovery in postnatal retinal development, synaptic pruning has been described
in many CNS disorders (reviewed in section 1.9). Additionally, other mechanisms of control
have also been identified. In the periphery, signal regulatory protein α (SIRPα) is a membrane
protein expressed on the surface of myeloid cells (Barclay and Van den Berg, 2014). SIRPα
interacts with CD47, which is associated with integrins αvβ3 (Jiang et al., 1999). The SIRPαCD47 interaction has been long known as a regulator of phagocytosis in the periphery (Barclay
and Brown, 2006). This is usually referred to as the “don’t-eat-me” signal. Previous work has
shown that CD47 is expressed on the synapses of neurons (Mi et al., 2000). SIRPα is also
expressed neurons and microglia in the CNS (Adams et al., 1998). Recent work from the Stevens
demonstrated that the SIRPα-CD47 interaction also regulates microglia mediated synaptic
pruning (Lehrman et al., 2018).
It has been hypothesized that disease processes, such as Alzheimer’s Disease, reactivate
synaptic pruning programs in microglia (Hong et al., 2016). Since REV-ERBα regulates
macrophage and hippocampal functions, we explored how this circadian protein regulated
microglial function and its consequences on synapses in the hippocampus. Microglia in the brain
parenchyma work in close concert with astrocytes, which are explored in the next sub-section.

1.7b Astrocytes
Astrocytes are the next relevant glial cell type investigated in this thesis. Unlike
microglia, which make up only 10% of the cells in the brain (Lawson et al., 1992), astrocytes are
the most abundant cell type in the brain – outnumbering neurons by over fivefold (Sofroniew and
Vinters, 2010). The first description of “neuroglia” was by Rudolf Virchow in 1858 in his
publication Die Cellularpathologie (Parpura and Verkhratsky, 2012). Over time, the concept
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evolved with in-depth investigations by Camillo Golgi and eventually the coining of the term
astrocytes by Michael von Lenhossék in 1891 (Parpura and Verkhratsky, 2012). Initially,
astrocytes were thought of as simple glue that held neuronal connections together (Araque et al.,
1999). However, our understanding of these cells has evolved since their initial description. Now
we know that astrocytes participate in various facets of neuronal function including synaptic
transmission, neuronal activity regulation, ionic regulation, and neurotransmitter clearance
(Sofroniew and Vinters, 2010).
Morphologically, astrocytes have thick and distinct branches that radiate from the soma
(Vasile et al., 2017). This is evident in Figure 1.7, which shows a human astrocyte labeled
diolistically (in white) and with glial fibrillary acid protein (GFAP) (in green). Since a single
astrocyte can contact as many as 100,000 synapses (Bushong et al., 2002), the extensively
branched structure is a critical component of their function. Astrocytes vary distinctly across
species (Vasile et al., 2017). The right panel of Figure 1.7 shows the difference between a mouse
and human astrocyte. Many believe that astrocyte complexity is the distinguishing feature of the
human brain itself (Oberheim et al., 2006). This has important implications for studies done in
mice. However, this thesis only assesses mouse astrocytes.
During vertebrate CNS development, radial glia cells are derived from the
neuroepithelium and serve as the neural stem cells that give rise to neurons, astrocytes and
oligodendrocytes (Kriegstein and Alvarez-Buylla, 2009). Neurogenesis generates neuroblasts,
which are then dedicated to the astrocyte fate via Polycomb signaling(Hirabayashi et al., 2009).
While the full details of differentiation are yet to be elucidated, it is known that Wnt, bone
morphogenic protein 2/4 (BMP 2/4) (Nagao et al., 2014) and β1-integrin signaling (Pan et al.,
2014) are crucial for astrogenesis.
Astrocytes play many roles in basal CNS function, including ion homeostasis,
neurotransmitter and amino acid level modulation, glycolysis, neural network organization and
rhythm generation, as well as calcium regulation (Allen and Eroglu, 2017). In addition to
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microglia, astrocytes are involved in the neuroinflammatory response to damage, disease and
infection (Sofroniew, 2015). During a response to an immune challenge, microglia can release
factors to induce astrocyte neurotoxicity (Liddelow et al., 2017).
Microglia and astrocytes work in concert to address, and sometimes contribute to, CNS
disorder sequelae (Andreasson et al., 2016). The specific diseases in which glia participate are
outlined in the next section. Considering the importance of astrocytes in generating circadian
rhythms (Brancaccio et al., 2019), we also investigated the potential role of REV-ERBα
disruption in astrocyte function.
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Figure 1.6 Comparison of Hortega depiction of Microglia (Pérez-Cerdá et al., 2015) to Confocal
Images taken 100 years later. Left: White matter drawing made by Pio Rio Del Hortega after staining with
the Golgi-Hortega method. Microglia are denoted by the M. Right: Immunofluorescence of Iba1 staining for
microglia in the hippocampus of a 6-month old mouse.
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Figure 1.7 Astrocyte morphologies across imaging methods and species. (Vasile et al., 2017)
Left: A human astrocyte imaged diostically (shown in white) as well as with GFAP labeling (in
the green within the inset). Right: Comparison of a mouse astrocyte (top) to human astrocyte
(bottom).
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1.8 Glia in Disease
The role of microglia and astrocytes (referred to in this document as glia) in disease is an
ever-evolving area of intense study. Since their discovery and characterization, the understanding
of glial biology has placed them firmly at the center of many neuropsychiatric and
neurodegenerative disorders. Various aspects of glial biology can become pathogenic if left
unchecked in the CNS. Here I discuss a few CNS diseases in which glia play crucial roles. While
this list is not exhaustive, it provides context for future experiments discussed in this thesis.
Alzheimer’s disease (AD) is the common form of dementia in the elderly and places a
significant burden on the healthcare system of United States and the world (2020). Although we
don’t fully understand the etiology of the disease, the neuropathological hallmarks of
extracellular amyloid beta (Aβ) plaques and intracellular tangles of the microtubule associated
protein tau have been identified in postmortem brains (Querfurth and LaFerla, 2010). Despite the
considerable effort by academic and industry labs, no effective disease-modifying therapies are
currently available. In the past, the amyloid hypothesis, which focused on Aβ plaques, steered
research efforts towards targeting that biology for a treatment (Hardy and Selkoe, 2002).
Although Aβ deposition is an early and necessary event for AD pathogenesis (Jack et al., 2013),
its utility as a therapeutic target has yet to be realized in the form of a drug. As such, researchers
have begun focusing on the other hallmarks of AD for therapeutic avenues. One of these is
neuroinflammation.
Like many other CNS disorders, AD is characterized by both astrocytic and microglial
activation (Andreasson et al., 2016). Furthermore, recent genome-wide association studies have
identified microglial genes as accounting for almost 50% of all AD-associated risk mutations
(Karch and Goate, 2015). Recently, mutations in microglial Triggering receptor expressed on
myeloid cells 2 (TREM2) were identified as strong risk factors for AD (Jonsson et al., 2013).
Microglia are the primary phagocytes of the central nervous system. In a disorder marked by the
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aggregation of proteins like Aβ and Tau, it is expected that microglia will phagocytose and
degrade these aggregates. However, the reality is complicated. Microglia can take up Aβ plaques
via CD36 and receptor for advanced glycation end product (RAGE) (Hickman et al., 2008).
Additionally, TREM2 facilitates the phagocytosis of debris by microglia (Colonna and Wang,
2016). Mutations in this uptake machinery impair microglia function and capacity to remove
debris. Microglia are so critical to AD pathogenesis that their depletion by using a colony
stimulating factor 1 (CSF1) inhibitor in AD mouse models reduces Aβ plaque number and
volume in cortical brain regions (Spangenberg et al., 2019). Transcriptomic analyses have
identified molecular signatures associated with microglia in the context of AD – these are known
as disease associated microglia (DAM) (Keren-Shaul et al., 2017a). These DAMs are more
phagocytic and downregulate homeostatic genes (Deczkowska et al., 2018).
Together with microglia, astrocytes help secrete a cocktail of proinflammatory molecules
including IL-6, IFN-γ, TNF-α, CCL2, IL-1β, and CCL4 in the brain during AD pathogenesis
(Akiyama et al., 2000). Damaged neurons can induce reactive astrogliosis, which is characteristic
of AD brains riddled with Aβ plaques (DeWitt et al., 1998). Reactive astrocytes can also regulate
microglial phagocytosis of Aβ plaques in AD brains (Verkhratsky et al., 2010). This illustrates
the bidirectional regulation between microglia and astrocytes in AD pathology.
Although multiple sclerosis (MS) is not as prevalent as AD, it is the primary cause of
non-traumatic disability in young adults (Noseworthy et al., 2000). MS is a demyelinating
disease marked by chronic inflammation and neurodegeneration (Amato et al., 2010). Even
without a full understanding of the disease etiology, it is known that microglia and astrocytes
play roles in disease pathogenesis and progression. Microglia are antigen presenting cells that
can recruit T cells through the expression of class I and II major histocompatibility complexes
(MHCs) (Luo et al., 2017). Astrocytes are capable of releasing TNF-α, IL-1β and IFN-γ, which
have been shown to induce intracellular adhesion molecule-1 (ICAM-1) and vascular cell
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adhesion molecule-1 (VCAM-1) – both of which, promote the migration of T cells into the CNS
(Nair et al., 2008). Since MS pathology is heavily dependent on T cells, glia play an important
role in the disease pathogenesis.
West Nile virus can induce a sequalae of symptoms that include severe and sometimes
fatal neurological disease that includes encephalitis, meningitis and anterior myelitis (Kelley et
al., 2003). Microglia respond to neurons infected with the virus, since they release more
nucleotides into the extracellular space (Chen et al., 2019). All three diseases discussed in this
section have one major feature in common – synaptic loss (Selkoe, 2002; Vasek et al., 2016;
Werneburg et al., 2020). The features of synapses in disease are discussed in the next section.
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1.9 Synapses in Health & Disease
The history of the discovery of the synapse traces all the way back to Ramón y Cajal. A
synapse is the gap between nerve terminal endings used for communication. Synaptic
transmission is fundamental to the network level integration in the brain. Initially, Camillo Golgi
believed that the cells of the brain formed a reticulum – i.e. all the cells were in contact with each
other (O'Brien, 2006). However, Cajal identified neurons as distinct entities in the 1880’s and
eventually Sherrington coined the term synapse in 1897 (O'Brien, 2006). Pioneering work by
Katz and colleagues elucidated the mechanisms behind communication at the synapse (Fatt and
Katz, 1952). While the details of synaptic transmission are complex, it all begins with the arrival
of the action potential at the presynaptic terminal. This triggers the release of neurotransmitter
that binds to receptors on the postsynaptic terminal and propagates the action potential.
Synaptic failure is an early symptom of AD (Selkoe, 2002), which makes sense
considering the eventual cognitive impairment that manifests in patients. As early as Braak Stage
III, synapse-rich regions of the brain, such as the hippocampus, display intense neurofibrillary
tangle pathology (Braak et al., 2006). This is associated with synaptic dysfunction early on in
disease progression – particularly in the molecular layer of the hippocampus (Scheff et al.,
2006). Electron microscopy imaging using osmium tetroxide showed fewer synapses in the
hippocampal molecular layer early on AD as seen in Figure 1.8. The molecular layer of the
hippocampus is synapse dense, therefore, changes in synaptic number or value are readily
detectable using immunohistochemical methods (Amaral et al., 2007). In the normal aged adult
brain, complement C1q is increased, while complement C3 is downregulated (Stephan et al.,
2012). However, in AD both C1q and C3 are upregulated, resulting in aberrant synaptic pruning
(Hong et al., 2016; Shi et al., 2017).
In MS, demyelination has been shown to trigger hippocampal synapse degeneration in
human patients (Dutta et al., 2011). Furthermore, studies using the experimental autoimmune
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encephalomyelitis (EAE) mouse model of MS found a reduction in post-synaptic density protein
95 (PSD-95) in the hippocampus (Bellizzi et al., 2016). Recently, a study from the Schafer lab
showed that microglia engulf synapses in MS models via a complement mediated mechanism
and blocking the complement activation rescues synapses and behavioral deficits (Werneburg et
al., 2020).
West-Nile virus has long been known to cause memory deficits in about 50% of patients
(Sejvar et al., 2003). However, the mechanisms were unknown until recently. Work from the
Klein lab demonstrated that synapses in the CA3 region of the hippocampus were aberrantly
pruned in a microglia-mediated complement dependent manner (Vasek et al., 2016).
Furthermore, T cells enhanced microglia-mediated synaptic pruning via IFN-γ signaling during
flavivirus infection (Garber et al., 2019). These are a few examples of how synaptic dysfunction
are part of neurologic disease sequalae. Given that circadian dysfunction can affect neurologic
disease, we also explored the potential effects on synapses in this thesis.
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Figure 1.8 Transmission electron microscope images of human brain tissue stained with osmium
tetroxide (Scheff et al., 2006). Images taken from the hippocampal dentate gyrus outer molecular layer
of human patients with (A) no cognitive impairment (B) mild cognitive impairment or (C) early
Alzheimer’s disease
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1.10 Objectives and Significance of Thesis
The circadian clock is a highly conserved system that helps organisms time their
physiology. Although REV-ERBα was discovered in the late 1980s, its function in regulating
brain macrophage function had not been explored. In this thesis, we explored the potential of
REV-ERBα to regulate one of the most important facets of microglia and astrocyte biology –
neuroinflammation. Given the ubiquity of neuroinflammation in disease, this represents a novel
therapeutic window to leverage the circadian clock to affect human disease.
First, we found that REV-ERBα gates neuroinflammatory states in both astrocytes and
microglia. This activation has profound effects on neuronal health on a number of different
scales – ranging from synapses to entire brain networks. Furthermore, the BMAL1-REV-ERBα
axis is a potent regulator of complement release in brain areas such as the hippocampus. The
aberrant reactivation of complement in these brain areas could explain the upregulation in the
observed synaptic pruning associated with REV-ERBα deletion.
Despite the description of circadian functions in multiple cell types, studies have not
explored circadian oscillation in brain macrophage function. Here, we show that both synaptic
pruning and microglial morphology, which correlates with activation, oscillate. These
oscillations are abrogated by the loss of REV-ERBα protein. However future studies are required
to fully elucidate regulatory mechanisms. Finally, we also show that synaptic protein expression
oscillates.
The establishment of oscillation in these previously unexplored areas of physiology raise
interesting future questions. Furthermore, research in these areas has to control for the variable of
time in future studies. If REV-ERBα is shown to be a significant regulatory protein in these
oscillating process, future work will have to explore the transcriptional mechanisms as well. This
work also present therapeutic opportunity. Since REV-ERBα is a nuclear receptor with existing
drugs that modulate its function, future work can explore how to leverage timing to affect human
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disease. Overall this work is novel in its exploration of glia and the protein REV-ERBα. It also
has significant implications for future drug development studies.
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Chapter 2: Role Of REV-ERBα in Regulating Glial Activation
2.1 Abstract
Circadian dysfunction is a common attribute of many neurodegenerative diseases, most
of which are associated with neuroinflammation. Circadian rhythm dysfunction has been
associated with inflammation in the periphery, but the role of the core clock in
neuroinflammation remains poorly understood. Here we demonstrate that REV-ERBα, a nuclear
receptor and circadian clock component, mediates microglial activation and neuroinflammation.
REV-ERBα, deletion caused spontaneous microglial activation in the hippocampus and
increased expression of pro-inflammatory transcripts, as well as secondary astrogliosis.
Transcriptomic analysis of hippocampus from REV-ERBα-/- mice revealed a predominant
inflammatory phenotype and suggested dysregulated NF-κB signaling. Isolated primary REVERBα-/- microglia exhibited pro-inflammatory phenotypes and increased basal NF-kB activation.
Chromatin immunoprecipitation (ChIP) revealed that REV-ERBα physically interacts with the
promoter regions of several NF-κB-related genes in primary microglia. Loss of REV-ERBα in
primary astrocytes had no effect on basal activation but did potentiate the inflammatory response
to lipopolysaccharide (LPS). In vivo, REV-ERBα-/- mice exhibited enhanced hippocampal
neuroinflammatory responses to peripheral LPS injection, while pharmacologic activation of
REV-ERBs with the small molecule agonist SR9009 suppressed LPS-induced hippocampal
neuroinflammation. Our results reveal REV-ERBα as a pharmacologically accessible link
between the circadian clock and neuroinflammation.
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2.2 Introduction
Circadian clocks allow organisms to precisely synchronize internal physiological
processes with the external environment. A conserved transcriptional-translational feedback loop
known as the core circadian clock controls cycles of protein expression that produce
transcriptional and physiologic rhythms. The core circadian clock consists of the transcriptional
activators BMAL1 and CLOCK, which drive transcription of their own transcriptional
repressors, including CRYPTOCHROME (CRY), PERIOD (PER), and REV-ERB proteins
(Mohawk et al., 2012). The circadian system regulates a variety of critical cellular processes,
including aspects of metabolism, inflammation, and redox homeostasis (Bass and Takahashi,
2010). Disruptions of the clock or its associated proteins have been implicated in pathological
conditions ranging from cancer, neurodegenerative diseases (Bass and Takahashi, 2010;
Kondratov, 2007; Musiek and Holtzman, 2016). However, the function of circadian clocks in the
brain is still poorly understood.
Microglia and astrocytes serve as the primary innate immune cells of the brain. Aberrant
glial cell activation and neuroinflammation are hallmarks of many neurodegenerative conditions
such as Alzheimer Disease (AD) and Parkinson disease (PD) (Heneka et al., 2015; Hirsch and
Hunot, 2009). Circadian disruption is also a common symptom of these diseases (Musiek and
Holtzman, 2016). The circadian clock has been implicated in the regulation of peripheral
inflammation (Druzd et al., 2017; Keller et al., 2009; Nguyen et al., 2013), though its role in
neuroinflammation is less clear. We have previously shown that deletion of Bmal1, which
disrupts core clock transcriptional function, causes widespread glial activation, inflammation,
and oxidative stress in the brain (Musiek et al., 2013), though the downstream mechanisms have
not been fully identified.
One potential mechanism by which BMAL1 could regulate neuroinflammation is via
transcriptional regulation of REV-ERBα (gene name Nr1d1). REV-ERBα is a heme-responsive
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nuclear receptor protein as well as a circadian clock component which is directly regulated by
BMAL1 (Kaech and Banker, 2006; Preitner et al., 2002; Raghuram et al., 2007). REV-ERBα is
also transcriptional repressor that inhibits Bmal1 expression and other targets at specific sites
within the genome in a tissue-specific manner(Lam et al., 2013; Preitner et al., 2002; Yin and
Lazar, 2005; Zhang et al., 2015). Additionally, REV-ERBα has been implicated in control of
diverse processes including metabolism, macrophage function, and inflammation (Cho et al.,
2012a; Gibbs et al., 2012). Because it is a nuclear receptor, REV-ERBα is an attractive
therapeutic target which can be modulated with available small-molecule agonists and
antagonists(Kojetin et al., 2011; Solt et al., 2012). While the function of REV-ERBα in
neuroinflammation and neurodegeneration has not been directly examined, REV-ERB agonist
drugs appear to prevent inflammation and cell death when infused into the brain(Guo et al.,
2018). Thus, we have examined the role for REV-ERBα in the control of neuroinflammation,
using genetic and pharmacological manipulations both in vivo and in vitro. Our results
demonstrate a key role for REV-ERBα in the regulation of glial activation and
neuroinflammation, which is associated with aberrant NF-kB activation in microglia and
neuronal dysfunction.

2.3 Materials and Methods
Mice: Both REV-ERBα+/- on a C57bl/6 background mice were obtained from The Jackson
Laboratory (Bar Harbor, ME) and bred at the mouse facility in BJCIH at Washington University.
Heterozygous mice were bred together to generate REV-ERBα+/+ (WT) and REV-ERBα-/(RKO) littermates which were used for experiments. Mice were housed on a 12/12 light/dark
cycle and fed ad libitum. All procedures performed on the mice were approved by the
Washington University IACUC.
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Antibodies: Primary antibodies used for Western Blotting (WB) and Immunohistochemistry
(IHC) are listed with target (IHC or WB, host, company, product number and dilution): GFAP
(IHC, rabbit, Dako/Agilent Z0334, 1:5000), GFAP (IHC (for co-staining), mouse, Novus
Biologics, Littleton, CO, NBP1-05197, 1:1000), MAP2 (IHC, mouse, EMD/Millipore, AB5622,
1:500), p42/44 ERK (WB, rabbit, Cell signaling Technologies, Danvers, MA, 9102, 1:1000),
CD68 (IHC, Rat, BioRad, MCA1957, 1:50) , p65(IHC, mouse, Cell Signaling Technologies,
6956, 1:1000), IκBα (WB, Mouse, Cell Signaling Technologies, 9936, 1:1000) , p-p65 (WB,
Rabbit, Cell Signaling Technologies, 9936, 1:1000)

Immunohistochemistry: Mice were anesthetized with intraperitoneal (i.p.) injection of
pentobarbital (150mg/kg), followed by pump perfusion for 3 mins with ice cold Dulbecco’s
modified Phosphate Buffered Saline (DPBS) containing 3g/l heparin sulfate. One hemisphere
was drop fixed in 4% paraformaldehyde (PFA) for 24 hours at 4˚C, then cryoprotected with 30%
sucrose in PBS also at 4˚C for 48 hours. 50µm serial coronal sections were cut on a freezing
sliding microtome and stored in cryoprotectant (30% ethylene glycol, 15% sucrose, 15%
phosphate buffer in ddH2O). Sections were washed 3 times in Tris buffered saline (TBS),
blocked for 30 mins in TBS containing 3% goat serum and 0.25% Triton X-100 (Sigma-Aldrich,
St. Louis, MO) then incubated in TBS containing 1% goat serum and 0.25% Triton X-100 with
primary antibody overnight at 4˚C. Sections were then washed 3 times and incubated for 1 hour
at room temperature with 1:1000 fluorescent secondary antibody and mounted on slides.
Epifluorescent images were obtained with the MetaMorph software on the Nikon Eclipse 80i
fluorescent microscope. Confocal images were taken on the Nikon Elements software with the
Nikon A1Rsi scanning confocal microscope. Z-stacks were taken at a step size of 0.1-0.3µm
from dark to dark through the tissue.
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Bitplane Imaris Analysis: Bitplane 9 image visualization and analysis software was used at the
Washington University Center for Cellular Imaging. For 3-D reconstructions, Z-stacks were
saved in the .nd2 file format and loaded into the Arena of the Bitplane software. 3-D surfaces
had a surface detail ranging from 0.1-0.3µm. For the Iba1-CD68 colocalization analyses, a
colocalization channel was built between the Iba1 and CD68 channels and the surface volume
was built and calculated from this channel. For the morphology visualizations, a surface-surface
colocalization volume was built between Iba1 and Iba1/CD68 colocalized volume. To quantify
the Iba1 volumes, 60X z-stacks were taken with 0.5µm step sizes in the mossy fiber region of the
CA3. The .nd2 files were imported into Bitplane 9 and surfaces were built from the
immunofluorescence z-stacks based on the Iba1 staining channel. The total volume of the surface
for each image was exported into excel for further quantification.

Skeletonize Analysis in ImageJ: 40X z-stacks were imported into ImageJ as a hyperstack. Then
we selected the Iba1 staining channel and applied the skeletonize plugin from the plugins menu
after drawing ROI’s for the microglia. After making the skeleton, we used analyze particles
function to count the number of branches/junctions.

IL-1β ELISA: We used the ELISA MAXTM Deluxe Set (Biolegend Cat #432606, Lot #B255417)
to quantify the IL-1β levels from media collected from BV-2 cells treated with 50ng/mL LPS
and increasing concentrations (0,1.25,2.5,5,10µM) of SR9009 to optimize a dose for primary
experiment treatment. Following this we collected media from primary microglia. The primary
microglia were stimulated with 50ng/mL LPS and/or 10µM SR9009 for 8hrs. Cells were treated
with 100mM ATP to allow for inflammasome maturation as well as to enhance IL-1β release
and 1mL of media was collected. We first optimized the dilutions by running a plate of
increasing concentrations of media from 1:1000 to 1:10 against the provided IL-1β standards.
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After optimizing the concentrations, we ran 4 replicates for each condition to quantify IL-1β
levels

Immunoreactivity Quantification: GFAP staining was quantified using ImageJ software (NIH).
GFAP 8-bit images had ROI’s draw by hand to encompass the regions of GFAP
immunoreactivity. A threshold value was set and maintained for all sections. GFAP percent area
coverage was then calculated for each image. MAP2 images were taken at 10X or 4X for percent
area quantifications. 3-5 images were taken per well and thresholded as above.

qPCR: Flash-frozen brain tissue was homogenized with a mechanical handheld homogenizer for
20 seconds in RNA kit lysis buffer (PureLinkTM RNA Mini Kit, Life Technologies, Carlsbad,
CA) plus 1% β-mercaptoethanol. RNA was then purified using the kit protocol. Cells well
collected and lysed in Trizol (Life Technologies). The aqueous layer was collected following
chloroform extraction (added at 1:5 then spun at 13000xg for 15 minutes) with RNA isolation
protocol. RNA concentrations were then measured using the Nanodrop spectrophotometer and
cDNA was made using a high capacity RNA-cDNA reverse transcription kit (Applied
Biosystems/LifeTechnologies) with 1µg RNA used per 20µL reaction. Real-time quantitative
PCR was performed with ABI Taqman primers and ABI PCR Master Mix buffer on the ABI
StepOnePlus 12k Real-Time PCR thermocyclers. β-actin (Actb) mRNA levels were used for
normalization during analysis.

Rev-erbα ChIP Analyses: Initial search for putative Rev-erbα binding sites were done using the
IGV and publicly available ChIP-Seq data sets for the liver (https://chipatlas.org/view?id=SRX3205285), brown adipocytes (https://chip-atlas.org/view?id=SRX163025)
and Ventral Tegmental area (Zhang et al., 2015). Chromatin immunoprecipitation was performed
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according to previously published work. (Gow et al., 2014) Briefly, we used the SimpleChIP®
Enzymatic Chromatin IP Kit (Cell Signaling Technology) on isolated WT primary microglia
grown to confluency in T75 flasks. Following revers cross-linking, the samples were purified
using the QIAquick PCR Purification Kit (Qiagen). Quantitative PCR (qPCR) was performed
using the SYBR qPCR master mix (Life Technologies). Chromatin binding was calculated as a
percentage of immunoprecipitated DNA relative the input amount. Data were expressed as mean
± standard deviation of duplicate samples from representative assays. The Rev-erbα antibody
used has been described previously (Welch et al., 2017). Good binding was determined as
compared to Gapdh binding. The primers had the following sequences
Gapdh Forward: AGTGCCAGCCTCGTCCCGTAGACAAAATG
Gapdh Reverse: AAGTGGGCCCCGGCCTTCTCCAT
Arntl Forward: ATTGGCTAACGGGAAGAGGC
Arntl Reverse: TACTTTCCGACCAATCCGCT
Traf2 Forward: CGCCGCTCTGACTAATCACC
Traf2 Reverse: AAATAGGCCGCCTTGACTCT
Nfkbib Forward: GGAAACTCAGCGAGCGAATG
Nfkbib Reverse: TAAATAGCTACACCCCGCCC
Nfkb2 Forward: CTTGTGAACCCGCCACTTAC
Nfkb2 Reverse: ATCTAGCGGCCTTTCTGGAG
S100a4 Forward: GTGTCCACCCCATCCAAGTC
S100a4 Reverse: ATGTCATAGCACCCTCGACC

Western Blotting: Tissue/cell samples were homogenized by sonication in
radioimmunoprecipitation assay (RIPA) buffer (Cell Signaling Technologies, Danvers MA).
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RIPA buffer contained complete protease inhibitors (Roche Life Sciences USA, Indianapolis,
IN). The samples were ran on nuPAGE Novex gels with SDS running buffer and transferred on
the iBlot2 transfer device (Life Technologies). Bands were visualized with Lumigen TMA-6
chemiluminescence reagents (Lumigen, Southfield, MI) on a Syngene GBOX Imaging System.
Band density was calculated using ImageJ software and normalized to ERK as the loading
control.

Primary Cell Cultures: WT astrocyte cultures were obtained from CD1 mice from Charles River
Laboratories (Wilmington, MA). Astrocytes were isolated from P0-2 pups. For experiments
involving REV-ERBα-/- astrocytes or microglia, the cultures were made from mice on a
C57BL/6J background. Cortices plus hippocampus were dissected and stripped of meninges in
ice-cold DMEM (Life Technologies) and then incubated in 0.05% Trypsin-EDTA at 37˚C for 20
mins (Astrocytes). Tissue was gently triturated in 37˚C DMEM plus 10% FBS (Gibco). For
astrocyte cultures cells were then plated in T75 flasks coated for 2 hours at 37˚C with 50µg/mL
poly-D-Lysine (PDL – MP Biosciences, Santa Ana, CA) then rinsed with ddH2O. Astrocytes
were then grown to confluence in DMEM, 10% FBS, and 1% Penicillin/Streptomycin (P/S) with
or without 5 ng/mL GM-CSF. For primary microglia isolation from GM-CSF containing media,
flasks were shaken at 225rpm at 37˚C for 2 hours and replated on plates coated with PDL. All
wells were then fixed with 4% PFA and stained. In general, all cell culture experiments were
performed in duplicate and repeated at least 3 times, using primary cells prepared from at least
separate dissections.

siRNA transfections: Astrocytes cultures were transfected with siRNA using lipofectamine
RNAiMAX (Life Technologies) in OptiMEM (Life Technologies) according to the
manufacturer’s instructions. After 48 hours media was changed to DMEM plus 10% FBS or
Neurobasal plus B-27 for conditioning. siRNAs targeting mouse Nr1d1 or non-targeting
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(scrambled and designed to target no known mouse gene) were obtained from Dharmacon
(Lafayette, CO). An siRNA to RNAiMAX ratio of 1:1.25 was used and 40 pmol of siRNA (2µL
of 20µM stock) was added to each well of a 12 well plate. Media was changed/collected every
48 hours.

2.4 Results
REV-ERBα
α deletion induces spontaneous microgliosis

α deletion induces hippocampal microglial activation. A,B. Iba1
Figure 2.4.1. REV-ERBα
staining in 5mo REV-ERBα -/- hippocampus (right panels) compared to WT littermate controls
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(left panels). C. qPCR analysis for microglial inflammatory genes from the hippocampus of WT
and REV-ERBα-/- mice. N=6 mice/group. D. Representative 3-D surface rendering showing
morphology of Iba1+ microglia, as well as Cd68+ puncta within Iba1+ positive cells (yellow), in
REV-ERBα-/- hippocampus compared to WT littermate controls. E. Quantification of Cd68/Iba1
colocalized puncta using Imaris software. N=12-14 reconstructed cells from 4 mice/genotype. F.
Representative skeletonized microglial reconstructions and G. quantification of the number of
branches per cell. N=3 mice, n = 35 microglia *P<0.05 or **p<0.01 by 2-tailed T-test with
Welch’s correction. Scale bars = 120µm.
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α increases microglial number and induces activation in young
Figure 2.4.2. REV-ERBα
mice. A. Number of Iba+ cells per 10X field of the hippocampus from WT or REV-ERBα -/mice. N = 6 mice per group. B. Normalized Iba-CD68 colocalization volumes for 2-3mo WT or
REV-ERBα -/- mice. N = 3 mice per genotype, n = 9 40X fields of view per genotype. C. qPCR
for proinflammatory marker transcripts stratified by age groups 2-3mo and 5-7mo in WT and
REV-ERBα -/- mice. N = 6 mice per genotype.

Since REV-ERBα has been shown to regulate macrophage function in the periphery
(Gibbs et al., 2012), we first investigated the effect of REV-ERBα deletion on the tissue resident
macrophages of the CNS - microglia. Accordingly, we observed markedly increased spontaneous
microglial Iba1 staining in the hippocampus of 5mo RKO mice (Fig. 2.4.1A, B), as well as
increases in microglial-related inflammatory transcripts in the RKO hippocampus, including Il1β
Ccl2, Aif1, and Trem2, consistent with a pro-inflammatory response (Fig. 2.4.1C). Microglial
activation can be characterized by morphologic changes, as well as increases in the phagocytic
marker CD68 (Schafer et al., 2012). We found a significant increase in CD68+ puncta within
Iba1+ microglia by confocal imaging with 3D surface reconstruction in the hippocampus of
RKO mice at 5-6 months of age, indicating increased phagocytic activation (Fig 2.4.1D, E,) We
also observed decreased microglial branching morphologic changes in RKO microglia,
consistent with activation (Fig. 2.4.1F,G)(Nayak et al., 2014). We observed an increase in total
number of Iba1+ microglia in the hippocampus of RKO mice (Fig 2.4.2A), as is noted in many
neuroinflammatory conditions. Young (2-3mo) RKO mice already had increased Iba1/Cd68
colocalization (Fig. 2.4.2B), as well as increased Aif1 and Trem2 expression, though Il1b
expression was age-dependent (Fig 2.4.2C), suggesting that only some component of the
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phenotype is age-dependent. Taken together, REV-ERBα appears to regulate microglial
activation.

Enhanced NF-κ
κB signaling is associated with immune activation in RKO microglia.

Figure 2.4.3. Rev-erbα-mediated neuroinflammation is associated with dysregulated
microglial NF-kB signaling. A. Relative expression of transcripts related to different aspects of
neuroinflammation taken from microarray analysis performed on 5mo RKO and WT mice
(N=3/genotype). Colored bars on left indicate hand-curated functional groupings. B. Gene
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Ontology (GO) Term analysis of microarray data for biological processes upregulated in RKO
hippocampus as compared to WT (p>0.05, fold change>2). C. Representative images showing
p65 nuclear translocation in RKO microglia compared to WT at baseline, 1hr, and 3hrs,
following LPS stimulation. Quantification of the % microglia with nuclear p65 staining
(DAPI/p65 overlap) is shown (right). N=3 separate experiments. D. qPCR showing mRNA
expression for the proinflammatory mediators Il6 and Tnfa in primary WT and RKO microglia.
E. ChIP analysis of WT microglia for the Rev-erbα target Bmal1, NFκB signaling components
Traf2 as well as Nfkbib, a negative control S100a4 and a normalization control Gapdh. *p<0.05
by 2-tailed T-test with Welch’s correction. ****p<0.001 by 2-way ANOVA with Tukey’s
multiple comparisons test.

Figure 2.4.4 A. qPCR validation of selected transcripts from the microarray data in a
separate cohort of mice (n = 5-6/group). *p<0.05 by Mann-Whitney test

To further characterize the neuroinflammatory phenotype of RKO mice, we performed
microarray-based transcriptomic analysis of hippocampal tissue from 5mo WT or RKO mice.
We observed significant increases in proinflammatory chemokines (Ccl2, Ccl5, Ccl8, Cxcl5),
astrocyte activation markers (Gfap, Timp1, S100a4, S100A6), and microglial activation
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transcripts (Aif1, Cd68, Tyrobp, Trem2, Csf1r) (Fig 2.4.3 A). We confirmed several of these
transcriptional changes by qPCR in a separate cohort of 5mo mice, including Timp1, S100a6,
and Cxcl5 (Fig. 2.4.4). Because REV-ERBα is a transcriptional repressor, we performed
pathway analysis of transcripts which were significantly upregulated (uncorrected p value<0.05,
fold change>2) using DAVID software, which showed profound upregulation of biological
processes related to innate immune activation and inflammation (Fig 2.4.3 B), emphasizing the
neuroinflammatory phenotype.
The NF-κB pathway is a critical regulator of innate immune activation which interacts
with Rev-erbα (Guo et al., 2018; Migita et al., 2004). We observed upregulation of several genes
involved in the positive regulation of NF-κB signaling, such as Nfkb2, Tlr4, Stat3 and Traf2,
were significantly increased in RKO hippocampus, as well as downregulation of two genes
involved in inhibiting NF-κB signaling (Nfkbib and Usp31)(Fig 2.4.3A). Of note, Nfkbib encodes
the NF-kB pathway inhibitor IκBβ (McKenna and Wright, 2015). We next examined basal and
LPS-induced p65 nuclear translocation in primary WT and RKO microglia. In WT microglia,
nuclear p65 was minimal at baseline, increased markedly 1 hour after LPS stimulation, then
decreased by 3 hrs after LPS (Fig. 2.4.3C). However, RKO microglia showed significantly
increased p65 nuclear translocation at baseline which remained elevated throughout the
stimulation (Fig. 2.4.3C). Accordingly, primary RKO microglia showed increased basal cytokine
production (Fig. 2.4.3D) We next performed chromatin immunoprecipitation (ChIP) assays in
primary microglia using Rev-erbα antibody or IgG control, to identify direct targets of REVERBα. Using existing ChIP-seq databases for liver, adipose, and midbrain tissue (Zhang et al.,
2015), we identified Rev-erbα binding peaks located in the promoter regions of several genes
which were altered in our transcriptomic data, including Traf2, Nfkb2, and Nfkbib. QPCR from
WT microglial ChIP DNA revealed strong REV-ERBαbinding to the promoters of Bmal1 (a
known Rev-erb target), Traf2, and Nfkbib, with lesser but still significant signal for Nfkb2 (Fig.
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2.4.3 E). S100a4, an astrocyte gene included as a negative control, showed no signal, while DNA
from RKO cells also showed no signal. These data suggest that loss of REV-ERBαdirectly
regulates expression of multiple NF-kB related genes to enhance basal NF-κB signaling in
microglia and promote pro-inflammatory microglial activation.

Rev-erbα
α deletion induces non-cell autonomous astrocyte activation.
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Figure 2.4.5. Astrocyte activation in Rev-erbα-/- brain is non-cell autonomous. A, B. GFAP
staining in the piriform cortex (A) and hippocampus (B) of 5mo RKO mice (KO, right panels)
compared to WT (left panels). C. Quantification of the percent area GFAP immunoreactivity in
the cortex of RKO (KO) and WT littermates at 2-5mo. N = 10-11 mice/genotype. D. Western
blot analysis for relative GFAP protein levels in WT and RKO mouse hippocampi as well as the
associated ERK loading control. E. qPCR analysis of Gfap mRNA expression in hippocampus
from 2-3mo and 4-5mo RKO (KO) and WT mice. N=10-12 mice/group. F. Average expression
fold changes for pan-reactive astrocyte activation markers in the hippocampus of 5mo Rev-erbα/-

, as compared to WT littermates, N=3 mice/genotype. G. qPCR for Gfap mRNA expression in

primary WT astrocytes treated with control siRNA as well as siRNA targeting Bmal1 and Nr1d1.
H. Relative mRNA expression levels for the Rev-erbα target Fabp7, and astrocyte activation
markers Gfap as well as Serpina3n in primary WT and RKO astrocytes. *p<0.05 by 2-tailed Ttest with Holm-Sidak correction for multiple comparisons.
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Figure 2.4.6. REV-ERBα
α deletion induces astrocyte activation in vivo and alters response
to LPS. A. GFAP staining in cortex (top panels) and hippocampus (bottom panels) of 3mo WT
and REV-ERBα-/- mice show early involvement of hippocampus outer cortical layers. B.
Quantification of percent area GFAP immunoreactivity in the hippocampus of 3mo and 5mo WT
and REV-ERBα-/- mice. C. qPCR for Nr1d1 and Bmal1 mRNA expression in primary WT
astrocytes treated with control siRNA as well as siRNA targeting Bmal1 and Nr1d1. D. mRNA
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expression of Il6 and Il1b in WT and REV-ERBα-/- astrocytes at baseline and treated with LPS.
*p<0.05 by 2-tailed T-test

Since astrogliosis is associated with microglial activation and occurs in Bmal1-/- mice (Musiek et
al., 2013), we next examined astrocyte activation in RKO brain. We observed diffuse astrocyte
activation, as assessed by increases in GFAP immunoreactivity (Fig. 2.4.5A-C), protein (Fig.
2.4.5 D), and mRNA (Fig 2.4.5 E) expression, throughout the cortex (Fig 2.4.5A, Fig. 2.4.6 A)
and hippocampus (Fig 2.4.5 B). Increases in mRNA expression is evident in 2-3mo and 4-5mo
RKO mice (Fig. 2.4.5 E). The degree of astrogliosis was variable between mice, though it was
consistently observed beginning in the outer cortical layers and hippocampus by 3mo (Fig. 2.4.6
A). We examined expression of pan-reactive astrocyte activation transcripts, as described
previously (Liddelow et al., 2017), and found the majority of these to be significantly
upregulated in RKO hippocampus (Fig 2.4.5 F). We have recently demonstrated the BMAL1
can regulate astrocyte activation in a cell-autonomous manner (Lananna et al., 2018b). However,
we observed no increase in Gfap expression in WT astrocytes following siRNA-mediated Nr1d1
knockdown (Fig. 2.4.5 G), or in primary astrocyte cultures from RKO mice (Fig. 2.4.5 H).
Notably, RKO astrocyte cultures did show increased Il6 and Il1b expression in response in to
LPS (Fig. 2.4.5 D), suggesting that REV-ERBα may regulate NF-kB in multiple glial cell types.
Thus, our results suggest that REV-ERBα deletion induces astrocyte activation indirectly,
perhaps as a result of microglial activation, neuronal injury, or other factors.
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Loss of REV-ERBα
α exacerbates LPS-induced neuroinflammation, which can be
suppressed by pharmacological activation of REV-ERBα
α

Figure 2.4.7. Rev-erbs modulate LPS-induced neuroinflammation in vivo. A. qPCR analysis
of the hippocampal tissue from 5mo RKO mice or WT littermates treated with i.p. LPS for 6 hrs.
B. ELISA for IL-1β levels in media from WT or RKO primary microglia treated with LPS alone
or in combination with SR9009 as well as ATP for inflammasome maturation. C. qPCR of WT
or RKO primary microglia treated with LPS alone or in combination with SR9009 for Il6 mRNA
expression. Gene expression is normalized to LPS-treated WT cells. D. mRNA expression of Il6
in WT astrocytes treated with LPS and/or SR9009. E. qPCR analysis of hippocampus from WT
mice pretreated with SR9009 or vehicle (Veh), and then stimulated with i.p. LPS for 6 hours. In
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both A and E, data is shown as fold increase from vehicle-treated wt mice (no LPS). *p<0.05 by
2-tailed T-test.

Figure 2.4.8. REV-ERB agonist mitigates proinflammatory mediator release in cell lines
and primary astrocytes. A. ELISA measuring IL-1β levels in the media from BV-2 cells treated
with LPS at increasing concentrations of SR900o to find an optimal dose for primary cell
treatment as well as ATP. B. qPCR for Tnfa and Il1b mRNA expression in WT primary
astrocytes treated with LPS and/or SR9009. *p<0.05 by 2-way ANOVA with Holm-Sidak
selected multiple comparisons test.

Based on our in vitro findings, we next investigated the neuroinflammatory response of
RKO mice to LPS. Notably, we observed an extremely high fatality rate specifically in RKO
mice following intracerebroventricular LPS injection, and thus employed intraperitoneal (i.p.)
LPS injections instead. I.p. LPS caused striking increases of inflammatory transcripts within the
hippocampus of WT mice 6 hours after injection (Fig. 2.4.7 A). Mice were perfused prior to
tissue harvest to minimize RNA contribution from inflammatory cells in blood. REV-ERBα
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deletion augmented LPS-induced expression of proinflammatory mediators in the hippocampus,
including Il6 and Ccl2, the astrocyte activation marker Gfap, and the oxidative stress-responsive
transcript Hmox1 (Fig 2.4.7 A). These data suggest that REV-ERBα deletion exacerbates the
LPS-induced neuroinflammation in vivo.
We next sought to determine if activating REV-ERBα could mitigate LPS-induced
neuroinflammation. REV-ERBα is an orphan nuclear receptor and thus can be activated using
brain permeant small molecule agonists such as SR9009 (Solt et al., 2012). To test the effect of
REV-ERBα activation on inflammation, cells were stimulated with LPS with or without SR9009
for 8 hours to activate NF-kB, with ATP added during the final 30 minutes to facilitate secretion
of IL-1β into the media. In BV-2 immortalized microglial cells, SR9009 exhibited dosedependent suppression of LPS+ ATP-induced IL-1β protein secretion (Fig 2.4.8A). In primary
WT microglia, SR9009 again inhibited LPS+ATP-induced IL-1β secretion (Fig. 2.4.7B), as well
as Il6 mRNA expression (Fig 2.4.7 C). SR9009 did not significantly suppress cytokine
expression in RKO microglia, suggesting some specificity of the drug for REV-ERBα (Fig.
2.4.7B, C). SR9009 also significantly suppressed LPS-induced Il6, Tnfa, and Il1b expression in
primary astrocyte-enriched cultures (Fig. 2.4.7D, Fig. 2.4.8B), suggesting that this agent can
mitigate inflammation across cell types in the brain. We next investigated the effects of SR9009
on LPS-mediated neuroinflammation in vivo in the hippocampus. WT mice were pretreated with
twice-daily injections of SR9009 (100mg/kg) or vehicle, at 7am and 7pm for 2 days, then
injected with LPS (2mg/kg i.p.). WT mice pretreated with SR9009 showed a diminished
response to LPS stimulation as evidenced by reduced levels of proinflammatory transcripts,
including Il6 and Ccl2, in the hippocampus 6h after LPS injection (Fig 2.4.7E). Together, these
data demonstrate that deletion of REV-ERBα exacerbates LPS-induced hippocampal
inflammation, while Rev-erbα activation with SR9009 mitigates it.
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2.5 Discussion
Here, we show that the circadian clock protein REV-ERBα regulates microglial
activation in vitro and in vivo, and that loss of REV-ERBα function promotes spontaneous
neuroinflammation. We observed that loss of REV-ERBα may lock brain microglia in a proinflammatory state. ChIP experiments revealed that REV-ERBα can interact with promoter
regions of transcripts involved in NF-κB signaling, with loss of REV-ERBα driving proinflammatory NF-κB activation in cultured microglia and in the mouse hippocampus. While
astrocyte activation was observed in the RKO brain, REV-ERBα deletion did not induce Gfap
expression in cultured astrocytes, suggesting that, in contrast to Bmal1 deletion(Lananna et al.,
2018b), astrocyte activation in this model is non-cell-autonomous. Activation of REV-ERBs
with the small molecule agonist SR9009 suppressed inflammatory gene expression in cultured
glia and in vivo. Taken together, these data implicate REV-ERBα as an important regulator of
neuroinflammation.
A growing literature supports the link between the circadian clock and mammalian innate
and adaptive immune function (Scheiermann et al., 2018). REV-ERBα regulates various aspects
of peripheral innate immune activation and cytokine release in various tissues. REV-ERBα has
been implicated in the regulation of pulmonary inflammation (Pariollaud et al., 2018), and in the
transcriptional suppression of inflammatory mediators, including IL-6 and CCL-2 (Gibbs et al.,
2012; Sato et al., 2014). REV-ERBα also controls circadian oscillations in the NLRP3
inflammasome, with REV-ERBα deletion exacerbating IL-1β production and toxin-induced
inflammatory hepatitis in mice (Pourcet et al., 2018a). Despite the wealth of information
regarding REV-ERBα in peripheral immune function, little is known about its role in innate
immune responses in the brain. Microglia exhibit robust circadian clock function and
inflammatory activation of microglia varies in a circadian manner (Fonken et al., 2015; Nakazato
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et al., 2017). Thus, loss of rhythmic REV-ERBα-mediated transcriptional repression could play a
key role in the regulation of microglial activation state, as demonstrated by our finding that
microglial Iba1 volume changes with time of day in a REV-ERBα -dependent manner. Of note,
RKO mice display nearly normal wheel-running activity due to compensation by REV-ERBβ
(Cho et al., 2012b; Preitner et al., 2002).Thus, the inflammatory phenotypes observed are not due
to gross circadian rhythm disruption. Future studies are needed to understand the circadian and
non-circadian transcriptional functions of REV-ERBs in various cell types in the brain.
We observed activation of the NF-κB pathway in both our primary microglia experiments
and RKO brain. This is consistent with the previously established links between NF-κB signaling
and the circadian clock (Hong et al., 2018; Spengler et al., 2012), and a recent study using a
REV-ERBα-targeted drug (Guo et al., 2018). Notably, our experiments showed enhanced basal
NF-κB p65 nuclear accumulation in RKO microglia. Our data suggest that loss of Rev-erbα
could promote NF-κB signaling by directly regulating transcription of several NF-κB-associated
transcripts, including Traf2, Nfkbib, and Nfkb2. Traf2 conveys pro-inflammatory signals from the
TNF receptor to NF-κB, and can promote inflammation in glia (Su et al., 2017). Rev-erbα
deletion leads to loss of repression at the Traf2 promoter and increased Traf2 expression.
Interestingly, REV-ERBα also binds to the Nfkbib promoter, but Rev-erbα deletion leads to
decreased Nfkbib expression, suggesting that REV-ERBα binding may either act to somehow
positively regulate Nfkbib transcription, or that the direct binding effects of REV-ERBα at the
Nfkbib locus are minor and are counteracted by some indirect effect. Since Nfkbib acts as an
inhibitor of NF-κB activation (McKenna and Wright, 2015), loss of Nfkbib expression in REVERBα -/- cells could also promote inflammation. In macrophages, REV-ERBα/β integrate
transcriptional signals from multiple damage-associated transcription factors, including NF-κB,
Nrf2, and Smad3 (Eichenfield et al., 2016), suggesting complex transcriptional regulation
55

programs beyond canonical NF-kB signaling. Adding to the complexity, REV-ERBs can repress
transcription by several distinct mechanisms, including DNA binding domain (DBD)-dependent
binding to RORE sites (Yin and Lazar, 2005), DBD-independent tethering by tissue specific
transcription factors (Zhang et al., 2015), altering enhancer RNA expression(Lam et al., 2013),
and modulating chromatin looping (Kim et al., 2018). Notably, the REV-ERBα binding regions
which we identified in Traf2 and Nfkbib did not contain canonical RORE sites, suggesting
possible DBD-independent regulation. Future ChIP-seq experiments will be needed to fully
elucidate the cell type–specific targets of REV-ERBα.
REV-ERBα is a nuclear receptor that can be targeted pharmacologically with existing
agonists (Solt et al., 2012). Previous studies show that REV-ERB agonists can suppress LPSinduced inflammatory cytokine production in C6 glioma cells and cultured microglia, and in the
murine brain following LPS infusion (Guo et al., 2018; Morioka et al., 2016). Our results are
consistent with these previous studies, but greatly expand upon them by demonstrating the
necessity of REV-ERBα for maintaining microglial homeostasis. Furthermore, we have
demonstrated that the anti-inflammatory effects of SR9009 are at least partially dependent on
REV-ERBα, as we observed a blunted anti-inflammatory response to SR9009 in REV-ERBα -/microglia. Our studies use SR9009 as proof-of-concept agent to demonstrate that development of
more potent REV-ERB agonists may be a viable strategy for treatment of neurodegenerative
pathology.
In summary, our data establishes a role for REV-ERBα in the control of microglial
activation and neuroinflammation. This work solidifies REV-ERBα as a potential therapeutic
target for treatment of neuroinflammation and illustrates the need for future study of the role of
REV-ERBα and REV-ERB-targeted therapies in neuroinflammatory and neurodegenerative
diseases.
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Chapter 3: BMAL1 and REV-ERBα Mediated Regulation of
Complement Activation, Neuronal & Synaptic Health
3.1 Abstract
The circadian clock has been shown to regulate various aspects of brain health including
microglial and astrocyte activation. REV-ERBα deletion influenced neuronal health, as
conditioned media from REV-ERBα -deficient primary glial cultures exacerbated oxidative
damage in cultured neurons. REV-ERBα -/- mice also exhibited significantly altered cortical
resting-state functional connectivity, similar to that observed in neurodegenerative models. Here
we report that deletion of the master clock protein BMAL1 induces robust increases in the
expression of complement genes such as C3, C4b and C1q in the hippocampus. Loss of
downstream REV-ERBα-mediated transcriptional repression led to increases in C4b in neurons
and astrocytes as well as C3 in microglia and astrocytes. REV-ERBα deletion induced
complement C3/C4b gene expression, synapse loss and increased microglial phagocytosis of
synapses in the CA3 region of the hippocampus. REV-ERBα -/- mice also exhibited significantly
altered cortical resting-state functional connectivity, similar to that observed in
neurodegenerative models. This work uncovers the BMAL1-REV-ERBα axis as a regulator of
complement expression and synaptic phagocytosis in the brain. Additionally, there are network
level effects on the brain when REV-ERBα is deleted. Here, we illuminate novel mechanisms of
brain connectivity regulation by the circadian clock.

3.2 Introduction
The circadian clock orchestrates 24-hour rhythms in various cellular processes through
transcriptional-translational feedback loops in most cells of the body (Takahashi, 2017). At the
core of the clock’s positive limb is the bHLH-PAS transcription factor BMAL1, which
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heterodimerizes with CLOCK or NPAS2 to drive the transcription of large sets of clockcontrolled genes (Mohawk et al., 2012). BMAL1 transcriptional targets include the negative limb
feedback regulator CRY and PER proteins, as well as REV-ERBα and β, nuclear receptors
which can also inhibit the actions of the positive limb (Preitner et al., 2002; Retnakaran et al.,
1994). Disruption of this circadian machinery is associated with various pathophysiological
states including cancer, diabetes and neurodegeneration (Everett and Lazar, 2014; Musiek and
Holtzman, 2016; Sulli et al., 2018). Deletion of BMAL1 abrogates circadian clock function and
leads to an 85% decrease in REV-ERBα expression in the brain (Musiek et al., 2013). REVERBα functions as a transcriptional repressor in many tissues, and has been implicated in
regulation of metabolism and inflammation(Everett and Lazar, 2014). Previous work from our
group shows that deletion of BMAL1 or its downstream target REV-ERBα causes
neuroinflammation and impaired brain functional connectivity (Griffin et al., 2019; Musiek et al.,
2013). Diminished BMAL1 and REV-ERBα expression have also been described in mouse
models of Alzheimer’s Disease (AD)(Lee et al., 2020a; Stevanovic et al., 2017). In AD,
memory-associated, synapse-rich regions such as the hippocampus are affected early in the
disease course (Braak et al., 2006). Synaptic loss also precedes neuronal death in
neurodegeneration (Selkoe, 2002). Circadian dysfunction is also a well-described symptom of
AD and other neurodegenerative diseases (Musiek and Holtzman, 2016; Videnovic et al., 2014).
Therefore, elucidating the how clock proteins regulate synaptic health is an important step in
understanding the connection between circadian dysfunction and neurodegeneration.
A wealth of recent studies has emphasized the critical role of the complement system of
the brain in regulating neuroinflammation and synaptic integrity. Synapses labeled with the
opsonins C1q and C3 (Stevens et al., 2007) were first described to be pruned by microglia during
development (Schafer et al., 2012). C4 protein, encoded by the mouse C4b gene, also contributes
to synaptic pruning by microglia in vivo (Sekar et al., 2016). Complement-dependent microglial
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synaptic pruning has also been implicated in the pathogenesis of neurodegenerative and
neuropsychiatric diseases (Hong et al., 2016; Litvinchuk et al., 2018; Sekar et al., 2016;
Werneburg et al., 2020). Microglial activation is subject to circadian regulation (Fonken et al.,
2015; Hayashi et al., 2013), and we have previously described that deletion of BMAL1 or REVERBα can induce microglial activation (Griffin et al., 2019; Musiek et al., 2013). Given the roles
of the clock in neurodegeneration and microglial activation, we explored a potential role of the
core clock in regulating synaptic health. Herein we establish a novel link between the BMAL1REV-ERBα axis, complement expression, functional connectivity and microglial synaptic
pruning in the hippocampus

3.3 Materials and Methods
Mice: The REV-ERBα+/- on C57bl/6 background mice were obtained from The Jackson
Laboratory (Bar Harbor, ME) and bred at Washington University. Heterozygous mice were bred
together to generate REV-ERBα+/+ (WT) and REV-ERBα-/- (RKO) littermates which were used
for experiments. Global Bmal1 KO (BMKO), Aldh1L1-CreERT2 +, and Bmal1fl/fl mice were
obtained from the Jackson Laboratory. Aldh1L1-CreERT2 +, and Bmal1fl/fl mice were bred
together to generate the astrocyte-specific Bmal1 knockout mice. Camk2a-iCre+;Bmal1fl/fl mice
were bred at University of Texas Southwestern. CX3CR1GFP mice were obtained from The
Jackson Laboratory. Mice were housed on a 12/12 light/dark cycle and fed ad libitum. All
procedures performed on the mice were approved by the Washington University IACUC

Immunohistochemistry Mice were anesthetized with intraperitoneal (i.p.) injection of
pentobarbital (150mg/kg), followed by pump perfusion for 3 mins with ice cold Dulbecco’s
modified Phosphate Buffered Saline (DPBS) containing 3g/l heparin sulfate. One hemisphere
was drop fixed in 4% paraformaldehyde (PFA) for 24 hours at 4˚C, then cryoprotected with 30%
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sucrose in PBS also at 4˚C for at least 48 hours. Brains were embedded in OCT and frozen in
acetone with dry ice. 12µm serial coronal sections were cut on a cryostat and mounted directly
onto the glass slides for synaptic pruning analysis or synaptic quantification. Sections were
washed 3 times in Tris buffered saline (TBS), blocked for 45 mins in TBS containing 20% goat
(or donkey) serum, 2% Mouse-on-mouse (M.O.M) blocking reagent and 0.4% Triton X-100
(Sigma-Aldrich, St. Louis, MO). Sections were then incubated in TBS containing 10% goat (or
donkey) serum, 8% M.O.M protein concentrate and 0.4% Triton X-100 with primary antibody
overnight at 4˚C. Sections were then washed 3 times and incubated for 4 hours at room
temperature with 1:1000 fluorescent secondary antibody in a solution of TBS containing 10%
goat (or donkey) serum, 8% M.O.M protein concentrate and 0.4% Triton X-100. For other nonsynaptic staining, 50µm serial coronal sections were cut on a freezing sliding microtome and
stored in cryoprotectant (30% ethylene glycol, 15% sucrose, 15% phosphate buffer in ddH2O).
Sections were washed 3 times in Tris buffered saline (TBS), blocked for 30 mins in TBS
containing 3% goat serum and 0.25% Triton X-100 (Sigma-Aldrich, St. Louis, MO) then
incubated in TBS containing 1% goat serum and 0.25% Triton X-100 with primary antibody
overnight at 4˚C. Sections were then washed 3 times and incubated for 1 hour at room
temperature with 1:1000 fluorescent secondary antibody and mounted on slides. Primary
antibody concentrations used were Synaptophysin (1:100), Homer1 (1:500), Iba1 (1:500), CD68
(1:250), GFAP (1:2500), C3 (1:500), Synaptoporin (1:1000), NeuN (1:1000). Confocal images
were taken on the Nikon Elements software on the Nikon A1Rsi scanning confocal microscope.
Z-stacks were taken at a step size of 0.5-1µm from dark to dark through the tissue.

Electron Microscopy Animals were perfused with a fixative mix consisting of 2.5%
glutaraldehyde + 2% paraformaldehyde (fresh, EM grade) in 0.15M cacodylate buffer with 2mM
CaCl2 (final concentrations). Brains were extracted, blocked, and 100 µm coronal sections were
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made using a Leica 1200S vibratome. Tissues were then washed 3 x 10 minutes in cold
cacodylate buffer containing 2mM calcium chloride, and then incubated in a solution of 1%
OsO4 containing 3% potassium ferrocyanide in 0.3M cacodylate buffer with 4mM calcium
chloride for 1 hour in the dark. Following incubation, tissues were incubated for 20 minutes in a
1% thiocarbohydrazide (TCH) solution, rinsed 3 x 10 minutes in ddH2O at room temperature
and thereafter placed in 2% osmium tetroxide (NOT osmium ferrocyanide) in ddH20 for 30
minutes, at room temperature. Tissues were washed 3 x 10 minutes at room temperature in
ddH2O then placed in 1% uranyl acetate (aqueous) and incubated at 4° overnight. Tissues were
incubated in a lead aspartate solution at 60°C oven for 30 minutes, washed 5 x 3 minutes in
ddH2O, and returned to the lead aspartate solution at 60°C for 30 minutes. Tissues were washed
3 x 10 minutes in room temperature ddH2O and dehydrated in 50%, 70%, 90%, 100%, 100%
acetone (anhydrous), 10 minutes each. Samples were embedded in Durcupan ACM resin and
polymerized 60°C oven for 48 hours. 70 nm slices were made using a Leica UC7
ultramicrotome, and sections were picked up on a Si wafer (Ted Pella, Redding, CA). Images
were acquired on a Zeiss Merlin FE-SEM using a solid state backscatter detector (8kV, 900pA)
at 7nm resolution with 5µs pixel dwell times and 4x line averaging. Large area scans of ~150µm
x 150 µm field of view were acquired and stitched using Atlas 5.0 (Fibics, Ottawa, Canada)

Synaptic volume and engulfment analysis/3D reconstructions Bitplane Imaris 9 visualization and
analysis software was used at the Washington University Center for Cellular Imaging. For all
analyses Z-stacks were saved in the .nd2 file format and loaded into the software. 3-D surfaces
had a surface detail ranging from 0.1-0.3µm. To quantify the volume of the synapses, we
generated 3-D surfaces from each of the synaptic markers (Synaptophysin, Synaptoporin and
Homer1). We used the Batch colocalization function to colocalize the Synaptophysin and
Homer1 volumes. The total volume for each Z-stack was summed. For the synaptic engulfment
analyses, we first generated volumes from synaptophysin, CD68 and Iba1 staining. We then
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colocalized the synaptophysin volume with the CD68 volume. The resulting volume was then
colocalized with the Iba1 volume to produce a final microglial synaptic engulfment volume. All
values were normalized to the average values for the control group in each experiment.

REV-ERBα ChIP Sequencing We used the SimpleChIP® Enzymatic Chromatin IP Kit (Cell
Signaling Technology) on isolated WT primary microglia grown to confluency in T75 flasks.
Following revers cross-linking, the samples were purified using the QIAquick PCR Purification
Kit (Qiagen). Chromatin binding was calculated as a percentage of immunoprecipitated DNA
relative the input amount. The Rev-erbα antibody used has been described previously (Welch et
al., 2017). Following chromatin immunoprecipitation, the samples were submitted for next
generation sequencing on either the HiSeq 3000 or NovaSeq platform at the Washington
University Genome Technology Access Center. The selected threshold was a 4-fold increase in
binding.

Primary Cell Cultures WT Neuronal and astrocyte cultures were obtained from CD1 mice from
Charles River Laboratories (Wilmington, MA). Neurons were isolated from E16-E18 pups and
astrocytes were isolated from P0-2 pups. For experiments involving Rev-erbα-/- astrocytes or
microglia, the cultures were made from mice on a C57BL/6J background. Cortices plus
hippocampus were dissected and stripped of meninges in ice-cold DMEM (Life Technologies)
and then incubated in 0.05% Trypsin-EDTA at 37˚C for 15 mins (Neurons) or 20 mins
(Astrocytes). Tissue was gently triturated in 37˚C DMEM plus 10% FBS (Gibco). For astrocyte
cultures cells were then plated in T75 flasks coated for 2 hours at 37˚C with 50µg/mL poly-DLysine (PDL – MP Biosciences, Santa Ana, CA) then rinsed with ddH2O. Astrocytes were then
grown to confluence in DMEM, 10% FBS, and 1% Penicillin/Streptomycin (P/S) with or without
5 ng/mL GM-CSF. For primary microglia isolation from GM-CSF containing media, flasks were
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shaken at 225rpm at 37˚C for 2 hours and replated on plates coated with PDL. For neuronal
cultures, triturated cells were transferred to a second tube to remove debris, then diluted in
Neurobasal (Life Technologies) plus B27 (Life Technologies) prior to plating on a bed of
astrocytes or a PDL-coated plate. For co-culture experiments, astrocytes were grown to
confluence following replating in 24-well plates and neurons were added immediately after
primary dissection at a concentration of 150,000 cells/mL in Neurobasal plus B27 supplement
and glutamine (Life Technologies). After 48 hours, 50% of the media was changed to
Neurobasal plus anti-oxidant free B-27 (AOF B-27, Life Technologies) and glutamine.
Following that, 50% media changes were done using Neurobasal plus AOF B-27 and glutamine
every 3 days until neuronal DIV 11 at which the experimental wells received H2O2 and the
controls received vehicle for 24 hours. All wells were then fixed with 4% PFA and stained. In
general, all cell culture experiments were performed in duplicate and repeated at least 3 times,
using primary cells prepared from at least separate dissections

Quantification and Statistical Analysis Statistical analyses were performed using GraphPad

Prism 8. We performed t-tests with Welch’s correction for multiple comparisons.
REAGENT or RESOURCE
Antibodies
Gfap – Rabbit polyclonal,
1:2500
C3 – Rat monoclonal,
1:500
Iba1 – Goat polyclonal,
1:500
Synaptophysin – Mouse monoclonal,
1:100
CD68 Rat monoclonal,
1:250
Homer1 – Rabbit polyclonal,
1:500
Synaptoporin Rabbit polyclonal,
1:1000

SOURCE

IDENTIFIER

Dako/Agilent

Cat# Z0334;
RRID: AB_10013482
Cat# NB200-540
RRID: AB_10003444
Cat# ab5076;
RRID: AB_2224402
Cat# ab8049;
RRID: AB_2198854
Cat# MCA1957;
RRID: AB_2074849
Cat# 160 003;
RRID: AB_887730
Cat# 102 002;
RRID: AB_261974

Novus Biologicals
Abcam
Abcam
BioRad
Synaptic Systems
Synaptic Systems
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NeuN – Mouse monoclonal,
1:1000
Virus Strain
AAV-CaMKIIa-mCherry
Chemical
Tamoxifen
Critical Commercial Assays
High Capacity RNA-to-cDNA Kit
Taqman Universal PCR Master Mix
PureLink RNA Mini Kit
Experimental Models: Organisms/Strains
B6.Cg-Tg(CAG-cre/Esr1∗)5Amc/J (CAGCreERT2 mice)
B6;FVB-Tg(Aldh1l1-cre/ERT2)1Khakh/J
(Aldh1l1-CreERT2 mice)
B6.129S4(Cg)-Arntltm1Weit/J (Bmal1f/f mice)
B6.129P2(Cg)-Cx3cr1tm1Litt/J (Cx3cr1- CreERT2
mice)
Oligonucleotides
Actb Taqman Gene expression assay
Nr1d1 Taqman Gene expression assay
C4b Taqman Gene expression assay
C3 Taqman Gene expression assay
Fabp7 Taqman Gene expression assay
Software
Imaris
Fiji

EMD/Millipore

Cat# 14-5698-82;
RRID: AB_2298772

UNC Viral Vector
Core

N/A

Sigma

Cat# T5648

Applied Biosystems
Applied Biosystems
Ambion/Life

Cat# 4387406
Cat# 4304437
Cat# 12183025

Jackson Labs

Cat# 004682

Jackson Labs

Cat# 029655

Jackson Labs
Jackson Labs

Cat# 007668
Cat# 005582

Applied Biosystems
Applied Biosystems
Applied Biosystems
Applied Biosystems
Applied Biosystems

Mm02619580_g1
Mm00520708_m1
Mm00437893_g1
Mm01232779_m1
Mm00437838_m1

Bitplane
https://fiji.sc/

Version 9
N/A

Optical Intrinsic Signal Imaging and Functional Connectivity Analysis: Following our
previously published protocols(White et al., 2011), mice were anesthetized with ketaminexylazine (86.9 mg/kg ketamine, 13.4 mg/kg xylazine) and allowed 15 min for anesthetic
transition. Mice were placed on a heating pad maintained at 37°C with and the head secured in a
stereotactic frame. The head was shaved and cleaned, a midline incision was made to reflect the
scalp, and the intact skull was kept moist with mineral oil. For imaging, sequential illumination
was provided at four wavelengths by light emitting diodes (LEDs) placed approximately 10 cm
above the head. Diffuse reflected light was detected by a cooled, frame-transfer EMCCD camera
(iXon 897, Andor Technologies) at a full frame rate of 30 Hz over the majority of the convexity
of the cerebral cortex (approximately 1 cm2). Forty-five minutes of data were collected in each
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mouse. Data from all mice were subject to an initial quality check prior to spectroscopic
analysis(Bauer et al., 2018; Bauer et al., 2014). Raw light levels in which temporal variation in
reflected light level intensity exceeded 1% for any wavelength were excluded from further
analysis. This preliminary analysis resulted in 10–45 minutes of data per mouse. For each pixel
the differential light intensity at each wavelength was converted to differential absorption. The
multi-wavelength absorption coefficient data were then converted to hemoglobin concentration
changes for each pixel and time point. All analyses were performed on oxygenated hemoglobin.
Data were filtered over the infraslow band (0.009-0.08 Hz) following previous human fMRI
algorithms(Fox et al., 2005), resampled from 30 Hz to 1 Hz, spatially normalized to the Paxinos
atlas, and only shared brain areas across all mice were further analyzed. For functional
connectivity analysis, global signal regression was performed for each mouse prior to any
functional connectivity analysis. Zero-lag correlation was computed for all pixel pairs within the
shared brain region to create a whole-cortex correlation matrix for each mouse. Regions of
interest were generated by decomposing the average whole-cortex correlation matrix calculated
for all mice (combined WT and KO groups) using principal component analysis (PCA) as we
have done previously(Kraft et al., 2017). This procedure generated a set of topographical maps
corresponding to brain regions common to all mice imaged. ROIs were defined by thresholding
the first 2 PCs at the 95% percentile for positive and negative values, resulting in 8 total ROIs.
Functional connectivity patterns for each ROI were generated by correlating the average time
courses within each region with time courses of all other brain pixels. To assess the topography
of pairwise correlation changes between WT and KO groups, we computed the difference
correlation matrices by subtracting the group-averaged, whole cortex KO matrix from that of the
WT group and applied spatial principal components analysis to the difference matrix.
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3.4 Results
Glial Rev-erbα
α-deficiency promotes neuronal death in a co-culture model

Figure 3.4.1. Loss of REV-ERBα
α in glia impacts neuronal health in vitro. A. GFAP/Iba1 costain of mixed glial culture used to generate the conditioned media (CM). B. Nr1d1 mRNA
levels in mixed glia following treatment with control or Nr1d1 siRNA. C,D. Representative 10X
images of MAP2 staining of neurons grown in CM from mixed glia treated with control (C) or
Nr1d1 siRNA(D). After 7 days in CM, neurons were treated with hydrogen peroxide (H2O2) for
24 hours. E. Quantification of MAP2 staining in C and D. N=51-60 wells/group from at least 3
separate experiments. **p<0.05 by 2-tailed T-tests with Holm-Sidak correction for multiple
comparisons.
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Figure 3.4.2. Loss of REV-ERBα
α in astrocytes alone does not exacerbate H2O2-induced
neuronal injury. A. MAP2 staining of WT neurons grown on WT primary astrocytes and treated
with increasing concentrations of H2O2. B MAP2 staining of WT neurons grown on RKO primary
astrocytes and treated with increasing concentrations of H2O2.C. The associated quantifications of
percent area MAP2 staining in A and B. There was no significant difference between the 2
astrocyte genotypes, as assessed by multiple T-test with Holm-Sidak correction.

Aberrant glial activation can result in neuronal damage in the context of disease. Therefore, we
explored the consequences of REV-ERBα deficiency on neuronal injury using a primary neuronmixed glia co-culture model. We prepared mixed glial cultures containing microglia and
astrocytes from post-natal WT mice, then treated cultures with siRNA targeting Nr1d1 (siNr1d1)
to knock down REV-ERBα, or with a non-targeting siRNA (siSCR) (Fig. 3.4.1 A,B). We
removed the siRNA, then prepared conditioned media (CM) from these mixed cultures. We then
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grew WT primary cortical neurons in CM for 7 days, then treated neurons with hydrogen
peroxide (H2O2) for 24h to induce neuronal oxidative stress and death. WT neurons grown in
siNr1d1 CM showed increased cell death at similar H2O2 concentrations compared to neurons
grown in siSCR CM (Fig 3.4.1C-E). In a separate experiment, we depleted microglia by shaking
(leaving 1-2% microglia (Lananna et al., 2018b)) from WT or RKO mixed glial cultures, leaving
astrocyte-enriched cultures. WT neurons were grown on the astrocyte enriched cultures and then
stressed with H2O2. Here, we observed no significant differences between WT neurons grown on
WT and RKO astrocytes (Fig. 3.4.2). This illustrates the necessity of microglial REV-ERBα
deficiency in promoting neuronal injury in vitro.
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Disruption of the BMAL1-REV-ERBα
α axis induces complement upregulation in multiple
brain cell types.

Figure 3.4.3. REV-ERBα
α regulates synaptic health modulators in multiple cell types
downstream of BMAL1. A. Relative expression of complement related transcripts taken from
microarray analysis performed on hippocampus from 5mo RKO and WT mice (N= 3/genotype)
as well as BMAL1 KO mice (N=2). B. qPCR analysis of 11month old WT and neuron-specific
Bmal1 KO mice (Camk2a-iCre+;Bmal1fl/fl) for complement genes (N=3-4/group). C. qPCR
analysis of WT and astrocyte-specific (Aldh1l1-iCre+;Bmal1fl/fl)Bmal1 KO mice for complement
genes (N = 5/group). D. qPCR analysis of WT and microglia-specific (Cx3cr1-iCre+;Bmal1fl/fl )
Bmal1 KO mice for complement genes (N = 4-8/group). E. qPCR analysis of control GFP or Cre
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virus primary neurons isolated from Bmal1fl/fl mice for Nr1d1, Fabp7, C4b, C3 (n = 4-5/group).
F. qPCR analysis of WT or RKO mouse cortices for complement genes (N= 5-10/group). G.
Representative 40X maximum intensity projections of 5mo WT or RKO mice stained for C3 and
GFAP as well as the associated normalized volumes for C3-GFAP staining (n=8, N=4/group). H.
Representative 40X maximum intensity projections of 5mo WT or RKO mice stained for C3 and
Iba1 as well as the associated normalized volumes for C3-Iba1 staining (n=8, N=4/group).
*p<0.05 **p<0.01 ***p < 0.001 by 2-tailed T-test with Welch’s correction

Figure 3.4.4. Complement and glial activation occur after development. qPCR analysis for
complement genes in CAGCre-BMAL1 KO mice and Cre- controls (N = 5-6/group).
****p<0.00001 by 2-tailed T-test with Welch’s correction.
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While analyzing our previously published transcriptomic dataset from Bmal1 KO
(BMKO) hippocampal tissue, we observed a striking upregulation of several complement
transcripts, in particular C4b and C3, two genes which are critical for synaptic phagocytosis (Fig
3.4.3A). Other complement related transcripts including C1qc, C1qb, C1qa C1ra, and C1rb were
also significantly increased in BMKO hippocampus (Fig 3.4.3A). C4b was similarly increased in
cerebral cortex samples from 4mo tamoxifen-inducible global BMAL1 KO mice (CAGCreERT2;Bmal1f/f) in which Bmal1 was deleted at 2mo, demonstrating that this is not a
developmental phenomenon (Fig 3.4.4).
To determine the cell type(s) in which BMAL1 deletion induces complement gene
expression, we examined cerebral cortex tissue from pan-neuron-(CamK2aiCre;Bmal1fl/fl)((Izumo et al., 2014), astrocyte-( Aldh1l1-CreERT2;Bmal1fl/fl )(Lananna et al.,
2018a) and microglia-specific (Cx3cr1-CreERT2;Bmal1fl/fl )(Parkhurst et al., 2013) BMAL1
knockout mice. Both astrocyte- and microglia-specific Bmal1 KO mice were treated with
tamoxifen at 2mo and harvested 2 months later. Notably, C4b mRNA was strongly induced in
the neuron-specific BMAL1 KO mice, while C3 was not (Fig 3.4.3B). C4b was also induced in
astrocyte-specific BMAL1 KO mice (Fig 3.4.3C). C4b, but not C3, was induced in global
inducible Bmal1 KO mice (CAG-CreERT2;Bmal1f/f) 2mo after gene deletion (Fig. 3.4.4) Under
basal conditions, neither C4b nor C3 was induced in microglia specific BMAL1 KO mice (Fig
3.4.3D). Deletion of BMAL1 in primary Bmal1fl/fl neuron cultures via infection with an AAV8Cre viral vector (versus AAV8-eGFP control) suppressed the BMAL1 transcriptional target
REV-ERBα (Nr1d1) by 85% and induced C4b expression but caused no increase in C3 (Fig
3.4.1E). BMAL1 deletion also increased expression of Fabp7 (Fig 3.4.3E), a known target of
REV-ERBα-mediated transcriptional repression (Schnell et al., 2014). This suggested that the
upregulation of C4b gene expression observed with loss of BMAL1 could be mediated by derepression as consequence of downstream REV-ERBα loss. Accordingly, global deletion of
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REV-ERBα caused striking increases in C4b, C3 and other complement transcripts in the
hippocampus as assessed by microarray analysis (Fig 3.4.3A) and confirmed in separate samples
by qPCR (Fig 3.4.3F). Increased C3 protein expression was observed in both activated astrocytes
(Fig 3.4.3G) and microglia (Fig 3.4.3H) in the hippocampus of 5mo REV-ERBα KO (RKO)
mice. The finding that Bmal1 deletion induces C4b mRNA early, but not C3. Rather, C3 mRNA
and protein are increased at later ages, suggest that REV-ERBα directly represses C4b
expression in neurons and astrocytes, but the induction of C3 in both BMKO and RKO brain is
likely secondary to inflammatory glial activation which occurs over time.
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REV-ERBα
α regulates microglial synaptic engulfment

Figure 3.4.5. REV-ERBα
α deletion enhances synaptic phagocytosis in the CA3 region of the
hippocampus. A. Masked synaptophysin staining from microglia in the CA3 of 4-6mo WT or
RKO mice sacrificed at 11AM. B. Masked colocalized synaptophysin/CD68 staining from
microglia in the CA3 of 4-6mo WT or RKO mice sacrificed at 11AM. C. Individual microglia
from the CA3 stained with Iba1, CD68, and synaptophysin from 4-6mo WT or RKO mice
sacrificed at 11AM. D. 3D surface rendering of microglia showing engulfed presynaptic material
in lysosomes with zoomed in lysosomal content from WT mice in Ei and RKO mice in Eii/Eiii.
F. Quantification of the normalized Iba1-CD68-Synaptophysin volumes from microglia in the
CA3 region of the hippocampus of 4-6mo WT and RKO mice (N = 15 and 12 respectively). G.
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Annotated, representative scanning electron micrographs of microglia in the CA3 of WT (Cyan)
or RKO (Royal blue) mice sacrificed at 11AM with zoomed in pictures of engulfed presynaptic
terminals in Hi and presynaptic terminals in contact with microglia in Hii, Hiii and Hiv. I.
Quantification of presynaptic terminals in contact with or engulfed by microglia in the CA3 of
WT or RKO mice. **p < 0.01,**** p<0.0001 by 2-tailed T-test with Welch’s correction.

We previously demonstrated that global REV-ERBα deletion induced microglial
activation in vivo (Griffin et al., 2019). Given those results and the observation of increased C4b
and C3 expression in RKO brains, we examined the possibility that these changes would enhance
synaptic phagocytosis in 4-6mo RKO mice. We primarily focused on the mossy fiber synapses in
the CA2/3 region of the hippocampus, as these large synapses (thorny excrescences) can easily
be stained and imaged using standard confocal microscopy. Triple-labeling of tissue sections was
performed with antibodies against synaptophysin (a marker of presynaptic neuronal terminals –
Fig 3.4.5A), CD68 (a microglial lysosome marker – Fig 3.4.5B) and Iba1 (to define microglial
cell bodies and processes – Fig 3.4.5C). CD68 was used to ensure that the colocalized synaptic
material was actually within the microglia phagosome. 3D reconstructions were made, and total
volumes of engulfed synaptic material were calculated. We noted a 10-fold increase in engulfed
synaptic material in the hippocampus of RKO mice compared to their WT littermates at 6mo
(Fig 3.4.5F). In the RKO microglia, we observed synaptic material in the microglial process and
cell body (Fig 3.4.5Eii, Eiii), whereas WT microglia only had engulfed synaptic material in the
cell body (Fig 3.4.5Ei).
To corroborate these results, we also performed large area scanning electron microscopy
(SEM) experiments of the CA3 region of 6mo WT and RKO mice. Using this method, we
visually confirmed an increased number of presynaptic terminals within or in contact with
microglia in the hippocampus of RKO mice compared to WT (Fig 3.4.5G, H, H(i-v), I).
Interestingly, in our RKO mice we noted a downregulation in the expression of the Sirpa gene,
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which codes for the protein SIRPα (Fig 3.4.5A). SIRPα was recently described as a surface
receptor on microglia that serves as a “do-not-eat-me” signal (Lehrman et al., 2018). Taken
together, our results suggest that REV-ERBα deletion induces changes in microglial signaling
that precipitates synaptic engulfment.

CA3 synapses are reduced by REV-ERBα
α deletion
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Figure 3.4.6. REV-ERBα
α deletion induces synapse loss in the CA3 without neuronal loss in
the dentate gyrus. A. 60X representative maximum intensity projections showing
synaptophysin staining in the CA3 of 4-6mo WT and RKO mice with the associated normalized
volume quantification (N = 15 and 12 respectively). B. 60X representative maximum intensity
projections showing homer1 staining in the CA3 of 4-6mo WT and RKO mice with the
associated normalized volume quantification. C. 60X representative maximum intensity
projections showing colocalized synaptophysin and homer1 staining in the CA3 of 4-6mo WT
and RKO mice with the associated normalized volume quantification. D. Representative
76

scanning electron micrographs of synapses (presynaptic terminal in red, postsynaptic terminal in
green) as well as the associated synapse counts for 4-6mo WT and RKO mice. Each datapoint is
an image. (N=2/genotype) E. 60X representative maximum intensity projections showing
synaptoporin staining in the CA3 of 4-6mo WT and RKO mice with the associated normalized
volume quantification (N=6/genotype). F. 40X representative maximum intensity projections
showing NeuN staining in the dentate gyrus of 4-6mo WT and RKO mice with the associated
normalized volume quantification (N = 3-4/genotype). *p<0.05, **p < 0.01, **** p<0.0001 by
2-tailed T-test with Welch’s correction.
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Figure 3.4.7. REV-ERBα
α deletion does not induce synapse loss in CA1. A. Representative
60X maximum intensity projects of synaptophysin staining in the CA1 region of WT or RKO
mice as well as the associated normalized volume quantifications (N = 5/group). B.
Representative 60X maximum intensity projects of Homer1 staining in the CA1 region of WT or
RKO mice as well as the associated normalized volume quantifications (N = 5/group). C.
Representative 60X maximum intensity projects of Colocalized Synaptophysin and Homer1
staining in the CA1 region of WT or RKO mice as well as the associated normalized volume
quantifications (N = 5/group).
Following our observations of synaptic pruning in the RKO mice, we investigated the
status of the synapses in the CA3 region of the hippocampus. Synapses were double labeled by
using the presynaptic marker synaptophysin and the postsynaptic marker homer1. In RKO mice,
we observed a significant decrease in the synaptic volume in the CA3 region of the hippocampus
by synaptophysin staining (Fig 3.4.6A), homer1 staining (Fig 3.4.6B) and their colocalization
(Fig 3.4.6C) compared to their WT littermates. To further confirm these results, we counted
synapses in large area SEM images from the stratum lucidum of WT or RKO mice. Again, we
noted a decrease in the number of synapses in the RKO mouse CA3 by SEM, as compared to
their WT littermates (Fig 3.4.6D).
To ensure that our observations were not due purely to changes in synaptophysin protein
expression in the presynaptic terminal, synapses were also stained with a second presynaptic
marker, synaptoporin, and quantified. Synaptoporin was used because it is enriched in the mossy
fiber synapses of the hippocampus (Singec et al., 2002). Again, we observed a similar decrease
in synaptic volume in CA3 of RKO mice compared to their WT littermates using synaptoporin
staining (Fig 3.4.6E). Interestingly, we did not observe significant differences in synaptic
volumes between WT and RKO mice in the CA1 region of the hippocampus (Fig 3.4.7A-C),
suggesting that some terminals may be more susceptible to loss than others. To determine
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whether the loss in synapses was due to a loss of neuronal cell bodies, we quantified the volume
of neuronal nuclei of the dentate gyrus, which project to CA3, via NeuN staining. We found no
significant difference between the neuronal nuclear volumes of the dentate gyrus between the
WT and RKO mice (Fig 3.4.6F). Taken together, our data suggest that deletion of REV-ERBα
results in robust synaptic loss in the CA3 region without obvious neuronal loss.

Altered resting-state functional connectivity in RKO mice

Fig. 3.4.8. Impaired cortical resting-state functional connectivity in REV-ERBα
α KO mice.
A. Functional parcellation of resting stage networks using the average correlation structure
across all mice studied. B. Resting state functional connectivity (FC) maps in WT and KO mice
(n=5-6 mice/genotype). Top row: Group-averaged retrosplenial FC. High correlation is indicated
by reds; anticorrelation by blues. KO mice exhibit reduced interhemispheric FC as well as
reduced anterior-posterior anticorrelations. Bottom row: Group-averaged somatosensory FC. WT
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mice exhibited lower interhemispheric FC compared to KO mice while both groups exhibited
qualitatively similar ipsilateral FC. C. Regional differences in correlation structure for each ROI
pair. Maps of FC for each ROI examined in A were compressed into a difference matrix for
quantitative evaluation of pair-wise regional FC between WT and KO. WT mice exhibit
significantly increased retrosplenial FC and significantly decreased FC in somatosensory regions
compared to KO mice (black boxes). Cortical regions: M=motor, R=retrosplenial,
S=somatosensory, C=cingulate. D. Spatial PCA performed on the whole cortex correlation
difference matrix assesses the topography of all pair-wise correlation differences across groups.
The first 2 PCs from this process explain 39% (PC1) and 16% (PC2) of the variance,
respectively. This unbiased approach reveals also differences in KO mice involving retrosplenial
(PC1) and somatosensory regions (PC2). Dotted black outlines of the ROIs are for reference.

Given the effects on neuronal injury in vitro and the effects on synapses, we next asked if
genetic deletion of REV-ERBα leads to impairment of systems-level brain function by
examining cortical resting-state functional connectivity (FC) using optical intrinsic signal
imaging (OISI) (White et al., 2011). Using OISI, changes in FC between different cortical
regions can be observed in healthy mice (Bumstead et al., 2017; Kura et al., 2018) or in models
of neurodegeneration (Bero et al., 2012; Musiek et al., 2013). We performed OISI in
anesthetized 5mo WT and RKO (KO) mice, using a region-of-interest approach (Fig. 3.4.8A).
Compared to WT mice, mice lacking REV-ERBα exhibited significantly reduced FC within
retrosplenial cortex (Fig. 3.4.8B,C), a region which is selectively affected in other
neurodegenerative models (Bero et al., 2012; Musiek et al., 2016). Interestingly, we also
observed significantly increased FC within the somatosensory region of KO mice compared to
WT mice (bottom row Fig. 3.4.8B boxed blue region, Fig. 3.4.8C).We next examined
quantitative, global FC differences between WT and KO mice, using spatial principal component
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analysis (PCA) of the group-averaged whole-cortex correlation difference matrix. The first 2
principle components, which explain 55% of the total variance between the groups, overlap
remarkably with the retrosplenial (PC1, 39% variance) and somatosensory (PC2, 16% variance)
regions examined above (Fig. 3.4.8D). Thus, REV-ERBα deletion causes in vivo changes in
regional FC which resemble those observed in other mouse models of neurodegenerative disease.

3.5 Discussion
In this section, we explore the downstream effects of the REV-ERBα mediated
neuroinflammation that was discussed in section 2. First, we note that glia that are deficient in
REV-ERBα are less capable of supporting neurons in conditions of oxidative stress (Fig 3.4.1).
However, the cell-autonomy of this effect seems to depend on the microglia, as astrocytes alone
that do not have REV-ERBα are fully capable of supporting neurons in conditions of oxidative
stress (Fig 3.4.2). This is in line with our previous discovery that REV-ERBα mediated astrocyte
activation requires the presence of microglia (Fig 2.4.6).
We also show that loss of the circadian protein BMAL1 causes upregulation of
complement gene C4b in neurons and astrocytes, as well as increase astrocytic C3 expression, all
via loss of downstream REV-ERBα-mediated transcriptional repression. Deletion of REV-ERBα
leads to microglial activation, increase C4b and C3 expression, and increased microglial synaptic
phagocytosis in CA3 region of the hippocampus. Our finding suggests that the BMAL1-REVERBα axis regulates daily rhythms in synaptic phagocytosis, and that loss of REV-ERBα derepresses complement gene expression and locks the brain in a pro-phagocytic state.
The mechanisms by which Bmal1 deletion leads to increased complement gene
expression are complex and multicellular but appear to depend on REV-ERBα. REV-ERBα
expression is decreased by ~85% following Bmal1 deletion, and REV-ERBα deletion
phenocopies the complement gene expression increases seen in Bmal1 KO brain. Indeed, it is
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well established that REV-ERBα functions as a transcriptional repressor (Harding and Lazar,
1995). Loss of REV-ERBα-mediated repression is a general mechanisms governing increased
transcript expression following Bmal1 deletion - as evidence by strong upregulation of the REVERBα repression target Fabp7 following Bmal1 deletion (Schnell et al., 2014). Notably, we
queried an existing REV-ERBα ChIP-seq database from brain tissue (Zhang et al., 2015) (GEO
Series GSE67962), and did not find any peaks corresponding to C4b or C3. However, REVERBα is known to regulate transcription not only by direct binding to RORE sites, but also by
regulating enhancer function and eRNA expression to alter gene expression in trans (Lam et al.,
2013, and by altering chromatin looping(Kim et al., 2018).Thus, it is likely that REV-ERBα
regulates C4b expression in one of these alternative ways which is not apparent by typical ChIPseq. Tissue-specific deletion of Bmal1 shows that this Bmal1-REV-ERBα axis controls C4b
expression in neurons and astrocytes, but less so in microglia. Recent single-nucleus RNAseq
data suggests that C4b is prominently expressed in oligodendrocytes (Zhou et al., 2020).
However, we have not yet evaluated the effect of BMAL1 or REV-ERBα deletion on C4b in this
cell type. Presumably, C4b expression is low in neurons and astrocytes under normal conditions
but is increased by Bmal1 or REV-ERBα deletion. Work from the Stevens and Carroll labs
identified C4b expression in neurons which then tagged synapses and facilitated synaptic
pruning, and showed that deletion of C4b prevent accumulation of C3 protein at synapses, as C4
protein in upstream of C3 activation in the classical complement pathway (Sekar et al., 2016).
Bmal1 KO and RKO mice at 5-6mo also show an increase in C3 transcript and C3 protein
in astrocytes. However, Tissue-specific Bmal1 deletion in neurons or astrocytes causes
pronounced C4b increases but no C3 increases, suggesting that C3 expression in astrocytes and
microglia is a secondary response to increased neuroinflammation in aged global Bmal1 KO or
RKO mouse brain. Global inducible Bmal1 KO mice also do not show C3 induction at 2mo posttamoxifen (despite high C4b expression), as these mice have not developed a full
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neuroinflammatory response at that age. Our data suggests that full induction of C3 in Bmal1 and
RKO brain requires a time-dependent inflammatory response. We previously showed that REVERBα deletion increased Traf2 expression and increased NFκB signaling (Griffin et al., 2019).
NFκB signaling has also been shown to increase C3 expression and release from astrocytes (Lian
et al., 2015). Thus, REV-ERBα loss could induce C3 in astrocytes through the induction of
NFκB signaling. We also noted an increase in C1q expression in RKO primary neurons,
microglia and whole hippocampus. In the classical complement cascade, C1 and C4 are upstream
of C3 (Zipfel and Skerka, 2009). Functionally, C4 loss is associated with less synaptic tagging
with C3 and thus less synaptic pruning (Sekar et al., 2016), suggesting that C4 expression can
drive C3-dependent synapse pruning. Additionally, we noted that REV-ERBα regulated the “donot-eat-me” signal Sirpa (encoding SIRPα) in our microarray data. Loss of inhibitory signaling
from SIRPα makes microglia more likely to prune synapses, since SIRPα is primarily expressed
on microglia in the CNS (Zhang et al., 2014). Therefore, our data suggest that de-repression of
C4b in neurons and Traf2 in astrocytes and microglia, as well as diminished Sirpa expression in
microglia, lead to a “perfect storm” of complement expression and microglial activation that
promotes synaptic phagocytosis.
We focused on the CA2/3 mossy fiber synaptic boutons because they are large and easily
labeled with 2 synaptic vesicle markers – synaptoporin and synaptophysin (Grosse et al., 1998).
However, we did not observe synapse loss in the CA1 region, which may represent a regional
variability in BMAL1-REV-ERBα mediated synaptic pruning. Certainly, it is possible that
certain synapses are more susceptible to pruning than others, and this should be addressed in the
future. We cannot exclude the possibility that REV-ERBα deletion causes neuronal damage,
which elicits microglial phagocytosis of dysfunctional synapses. Indeed, neuronal C4b
upregulation could be a damage signal. However, the absence of neuronal cell body loss in the
dentate gyrus of RKO mice shows that there is no overt neurodegenerative response. These
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dentate gyrus granule cells give rise to the mossy fiber boutons in the CA3 (Scharfman and
Myers, 2012), which are clearly decreased in RKO mice. Thus, the effect of REV-ERBα appears
to be specific to the synapses.
We demonstrate that Rev-erbα KO mice have impaired functional connectivity in the
retrosplenial cortex, similar to other mouse models of neurodegeneration, including models of
amyloid-β or tau aggregation, or Bmal1 deletion (Bero et al., 2012; Musiek et al., 2013; Musiek
et al., 2016). It is unclear if this is due to damage related to neuroinflammation, or a direct effect
of Rev-erbα in neurons. Rev-erbα is known to regulate dopaminergic neurotransmission via
transcriptional control of tyrosine hydroxylase in the hippocampus and midbrain (Chung et al.,
2014b; Jager et al., 2014a), and Rev-erbα deletion alters cerebellar neuron development
(Chomez et al., 2000), suggesting that Rev-erbα could directly regulate cortical neuron function
and/or health. Future studies, using cell type-specific Rev-erbα deletion, are needed to delineate
the role of neuronal versus glial Rev-erbα in brain homeostasis.
This work has clear implications for neurodegenerative and neuropsychiatric diseases,
which have been linked to circadian disruption as well as complement dysregulation and synapse
loss. Since REV-ERBα is a nuclear receptor with available small-molecule ligands (Solt et al.,
2012), our findings suggest that it could be a therapeutic target for neurological and psychiatric
disease. In previous studies in the brain, activation of REV-ERBs appears to suppress microglial
cytokine production (Griffin et al., 2019) while inhibition of REV-ERBs can induce microglial
amyloid-beta uptake and decrease plaque burden in mice (Lee et al., 2020a). Effects on synaptic
engulfment should be considered as REV-ERB-based therapeutics are developed.
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Chapter 4: Time of Day of Effects on Microglial Activation and
Synaptic Health
4.1 Abstract
Given that REV-ERBα and BMAL1 play important roles in the circadian clock, we
investigated potential roles of time-of-day on synaptic health and microglial biology. We
assessed microglia activation, synaptic protein expression and synaptic pruning. We already
found that, deletion of REV-ERBα regulated these processes. Therefore, we assessed the
synaptic protein expression, microglia-mediated synaptic pruning and microglial activation at
11AM (ZT5), when REV-ERBα expression peaks, and 11PM (ZT17) when REV-ERBα
expression. Since REV-ERBα serves as transcriptional repressor, it follows that low levels could
potential be linked to greater microglial activity. Here, we demonstrated that microglial
morphology, which tracks with activation, oscillated by time of day. Microglia at 11AM had
lower volume than those at 11PM. However, this oscillation was abrogated in the REV-ERBα
KO mice. These microglia were constantly locked in the higher volume state. Given the
oscillations in microglia activation, we also assessed synaptic pruning by time of day. Similarly,
we found that more synapses were pruned at 11PM compared to 11AM. Furthermore, synaptic
proteins including Synaptophysin, Synaptoporin and Homer1 displayed oscillations in
immunoreactivity and volume. At 11AM, there was greater synaptic volume than at 11PM.
These experiments establish a previous undescribed oscillation in synaptic regulation and
microglial activation. It has important implications for glial biology and their consequences on
neuronal health.
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4.2 Introduction
Diurnal oscillations have been observed in myriad physiological process. One of these
processes, is the brain’s response to the inflammogen LPS (Paladino et al., 2010). The
oscillations in gene expression are extensive, even in the periphery, as demonstrated by a recent
paper from the Hogenesch lab (Ruben et al., 2018). Oscillation in the metabolic, endocrine and
behavioral function have been observed in humans (Skarke et al., 2017). Unsurprisingly, rhythms
have also been found in the response to hospital treatments (Ruben et al., 2019). This has
encouraged a shift to greater consideration of time-of-day in human disease treatment – also
referred to as chronotherapy.
Chronotherapy dates back to the 1970s, when leukemic mice were shown to have a better
response to drugs administered in decreasing doses over the course of 24-hours (Haus et al.,
1972). In humans, one study showed that outcomes from perioperative myocardial ischemiareperfusion injury brought on by on-pump cardiac surgery varied by time of day, and could be
prevented in mice by antagonizing REV-ERBα (Montaigne et al., 2018). These are a few
examples of studies that have laid the groundwork for future work into how the clock can be
leveraged to treat human disease.
Mechanistically, circadian clock proteins are inextricably linked to the cell cycle proteins.
In hepatocytes, it has been shown that the BMAL1-REV-ERBα/β axis regulates p21Waf1/CIP1,
which inhibits cell cycle progression during the G1 phase (Gréchez-Cassiau et al., 2008).
Additionally, PER proteins are also components of the cell cycle checkpoint system, such as
ataxia telangiectasia mutated (ATM)-checkpoint kinase 2 (Chk2) and ataxia telangiectasia and
Rad3-related (ATR) Chk1, which are both needed for the DNA damage response (Kondratov and
Antoch, 2007). However, most of these studies have been done in the periphery.
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In the brain, it has been proposed that sleep is required to renormalize synaptic strength
after a transient during the awake period (Tononi and Cirelli, 2014). The synaptic homeostasis
hypothesis (SHY) postulates that sleep is a critical process for brain plasticity and that sleep
serves to downregulate synpases (Tononi and Cirelli, 2003)This process is so important that
sleep deprivation has been shown to cause striking synaptic spine density loss in the middle of
the stratum radiatum – which is between CA1 and CA3 (Havekes et al., 2016). These synapses
play known roles in plasticity, learning and memory (Harris and Weinberg, 2012). Given the
known differences in synaptic ultrastructure based on sleep and the interactions of microglia with
synapses, we investigated potential oscillations of synapses, glia and their interactions by time of
day.

4.3 Materials and Methods
Stereotactic surgery and Intracortical viral injections CX3CR1GFP mice had their heads shaved
and ear bars put in bilaterally. Iodine was then applied and the skin over the skull was cut open
gently using surgical scissors. The skull was checked to make sure that it was level on both sides
of the midline. A hole was drilled through the skull but not into the brain parenchyma. The
coordinates used for the retrospenial cortex were 0.3mm mediolateral (M/L), -2mm anteriorposterior(A/P) and -1mm dorso-ventral(D/V) with bregma as a reference. The needle was placed
in the target location and then allowed to rest for 2 mins before infusion. The AAV2-CaMKIImCherry virus was obtained from the UNC viral vector core and infused at a rate of 0.2µL/min.
In total, the mice were injected with 2µL in the retrospenial cortex. After the infusion, we waited
5 mins for the virus to diffuse in the parenchyma and then the needle was slowly removed. The
skin over the skull was then stitched up and antibiotic was applied to the area. The mice were
then allowed to recover in an empty cage on a heating pad. After the surgery the mice were
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checked twice daily, 4 hours apart to ensure survival for 3 days. The mice were then allowed to
age for 1 month before being sacrificed for sectioning and imaging
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4.4 Results
Time-of-day variation in microglial morphology

Figure 4.4.1. REV-ERBα
α deletion abrogates oscillation in microglial morphology. A. 60X
images of Iba1 staining in 6-8mo WT (left panels) and RKO (right panels) mouse hippocampus,
with Iba1 volume quantification (B). Mice were sacrificed at ZT5 (11AM, top panels) and ZT17
(11PM, bottom panels). N = 4-5 mice/genotype, 3 images per mouse* P<0.05 or **p<0.01 by 2tailed T-test with Welch’s correction. Scale bars = 50µm for A.

We placed 6-8 month old (mo) wild type (WT) and Rev-erbα-/- mice (referred to as RKO
throughout) in constant darkness, then performed microglial staining with Iba1 at ZT5 and ZT17,
timepoints at which REV-ERB-regulate gene Fabp7 shows peak and trough expression,
respectively (Gerstner et al., 2008). We observed that in the WT hippocampus, microglial
volume varied by time-of-day, with increased Iba1 volume observed at ZT17 (trough expression
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for REV-ERBα-regulated targets) (Fig. 4.4.1 A,B). This time-of-day effect was abrogated in the
RKO mouse hippocampus, as microglial volume was similar to the WT ZT17 timepoint at both
ZT5 and 16 (Fig. 4.4.1 A,B). This finding suggested that oscillations in Rev-erbα may regulate
genes which control basal microglial activation state.

Time-of-day variation in microglial phagocytosis is regulated by REV-ERBα
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Figure 4.4.2. Microglial phagocytosis oscillates. 3D surface rendering of Iba1, CD68 and
synaptophysin in microglia from 6 mo WT mice sacrificed at A. 11AM or B. 11PM. Bi. Zoomed
in rendering showing an engulfed synaptophysin in microglia from WT mice sacrificed at 11PM.
C. The normalized volume of Iba1-CD68-Synaptophysin showing microglial phagocytosis of
synapses. (N=5/genotype) Representative scanning electron micrographs of microglia in the CA3
of WT mice sacrificed at D. 11AM or E. 11PM as well as Ei.a zoomed in picture of presynaptic
terminals within the microglia. F. Quantification of presynaptic terminals in contact with or
engulfed by microglia in WT mice sacrificed at 11AM or 11PM. (N=2/genotype) Representative
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100X images of microglia and neuronal axons from 6-8mo CX3CR1GFP mice injected with an
AAV2-CamKII-mCherry and sacrificed at G. 11AM or H. 11PM as well as the I. associated
quantification of the engulfed mCherry volume per microglia. (n=50,N=2/genotype) J.
Normalized volume of Iba1-CD68-Synaptophysin for WT or RKO mice sacrificed at 11AM or
11PM. (N = 4-12/group) *p < 0.05, ****p<0.0001 by 2-tailed T-test with Welch’s correction.

In the brain, REV-ERBα displays daily oscillation on the mRNA level – with its peak at
zeitgeber time (ZT) 8 (2pm) and its trough at ZT20 (2am) (Chung et al., 2014a). We have also
previously described oscillations in microglial activation, with low activation at ZT5 and high
activation at ZT17 (Griffin et al., 2019). Consequently, we investigated microglial synaptic
engulfment at different times of day. WT(C57BL/6) mice sacrificed at ZT5 (11AM) or ZT17
(11PM), and hippocampal sections were triple labeled with Iba1, CD68, and synaptophysin.
Microglia from the CA3 region of the hippocampus in mice sacrificed at ZT17 showed
significantly more engulfed presynaptic protein than those at ZT5 (Fig 4A, Fig 4B, Fig 4Bi, Fig
4C). To further establish these findings, we used large area SEM to count the number of
presynaptic terminals in contact with or within microglia at ZT5 or ZT22. In that experiment, we
also noted a higher number of presynaptic terminals in contact with and within the microglia at
ZT17 (Fig 4D, Fig 4E, Fig 4Ei, Fig 4F). As a final confirmation of this finding, we injected
CX3CR1GFP mice, which express GFP in microglia (Jung et al., 2000), with an AAV-CaMKIImCherry viral vector in the retrospenial cortex. 4 weeks later, we collected brain samples at ZT5
and 17, and calculated the volume of mCherry+ material in individual GFP+ microglia. Here, we
found that despite interactions between microglia and neurons at both timepoints, microglia at
11PM (CT17) engulfed more mCherry than those at 11AM (ZT5) (Fig 4G-I). RKO mice
harvested at ZT5 and 17 showed a persistently increased level of synaptic engulfment in
microglia, but with no time-of-day variation (Fig 4J), suggesting that daily oscillations in REVERBα may mediate rhythms in microglial synaptic phagocytosis. Overall, our data establish a
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REV-ERBα-dependent rhythm for the engulfment of neuronal materials in the brain parenchyma
by microglia.

Time-of-day variation in synaptic protein expression
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Figure 4.4.3 Time-of-day oscillation in synaptic protein expression. A. 60X representative
maximum intensity projections showing Synaptophysin staining in the CA3 of 6mo WT mice
sacrificed at 11AM or 11PM as well as the associated normalized volume quantification (N =
6/group). B. 60X representative maximum intensity projections showing Homer1 staining in the
CA3 of 6mo WT mice sacrificed at 11AM or 11PM as well as the associated normalized volume
quantification (N = 6/group). C. 60X representative maximum intensity projections showing
colocalized Synaptophysin-Homer1 staining in the CA3 of 6mo WT mice sacrificed at 11AM or
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11PM as well as the associated normalized volume quantification (N = 6/group). D. 60X
representative maximum intensity projections showing Synaptoporin staining in the CA3 of 6mo
WT mice sacrificed at 11AM or 11PM as well as the associated normalized volume
quantification (N = 6/group). E. qPCR for Nr1d1 and C4b in the hippocampus of 4-6mo
CX3CR1-GFP at 4 different times of day – 5AM, 11AM, 5PM and 11PM (N = 3-4/group). F.
Quantification of synapse counts for 4-6mo WT mice sacrificed at 11AM and 11PM, imaged
using electron microscopy. Each datapoint is an image. (N=2/genotype).

REV-ERBα protein has been shown to peak early in the day ZT5 and experience a trough
late at night ZT18 (Feng et al., 2011). Mass spectrometry studies have been used to establish
cycles in the phosphorylation of synaptic proteins in the forebrain (Brüning et al., 2019).
Furthermore, the synaptic transcriptome has also been shown to regulated by one of the most
important circadian processes – sleep (Noya et al., 2019). As such, we explored potential
changes in synaptic protein expression by time of day. We observed ~ a 90% decrease in
synaptophysin volume at 11PM compared to 11AM (Fig 4.4.3 A). We also found that Homer1
volume dropped by ~ 60% at 11PM (Fig 4.4.3 B). The colocalized volume of the pre- and
postsynaptic markers was also decreased by ~ 90% at 11PM compared to 11AM (Fig 4.4.3C). To
ensure that this phenomenon was not due to the chosen presynaptic marker, we also stained with
Synaptoporin. Interestingly, synaptoporin volume was decreased by only ~ 50% at 11PM
compared to 11AM (Fig. 4.4.3D). Although the magnitude is not as striking as the
synaptophysin, the synaptoporin results still follow the same trend. We confirmed these findings
using transmission electron microscopy. Synapse counts were reduced by ~50% in the CA3
regions of mice at 11PM compared to 11AM (Fig 4.4.3F). Complement C4 has been shown to
be deposited on synapses that are targeted for degradation (Sekar et al., 2016). Given are
previous results showing that REV-ERBα regulates synaptic pruning, we explored a potential
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interaction between C4b and Nr1d1 expression. Interestingly, we found an antiphase relationship
between Nr1d1 and C4b expression in the hippocampus of CX3CR1-GFP mice (Fig 4.4.3 E).

4.5 Discussion
We observed a time-of-day effect on microglial immunoreactivity in the hippocampus
which was lost following Rev-erbα deletion, suggesting that Rev-erbα may control circadian
oscillation of microglial activation, and that loss of Rev-erbα may lock brain microglia in a proinflammatory state. We also establish REV-ERBα as a regulator of microglial synaptic
phagocytosis. Herein, we observed that microglia engulfed more synapses in the CA3 of the
hippocampus at 11PM (ZT17) than at 11AM (ZT5). This was evident by both
immunofluorescence and by electron microscopy. To further confirm this striking finding, we
used a viral approach in which the retrospenial cortex of mice with GFP labeled microglia had
neurons labeled with an mCherry expressing virus. In this paradigm, microglia engulfed more
mCherry at 11PM (ZT17) than at 11AM (ZT5). Finally, REV-ERBα deletion abrogated this
time-of-day variation in synaptic protein phagocytosis, as RKO mice had high levels of
phagocytosis at both timepoints. This data parallels our previous findings with microglial
morphologic changes and suggests that REV-ERBα mediates daily changes in the degree of
microglial synaptic engulfment. Also, REV-ERBα deletion locks the system in one of the
extremes of this naturally occurring oscillation. The importance of REV-ERBα in regulating
macrophage function is well-established in the literature. However, functional variation over the
course of the day in the brain has important implications for future therapeutic design studies. In
the past, studies involving the role of microglia in neurodegenerative disease have focused on
facets of their biology such reactive oxygen species generation, amyloid uptake, pattern
recognition and synaptic remodeling (Hickman et al., 2018). This work demonstrates that
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microglial activation and its consequences are under circadian regulation. As such they need to
be considered for neurodegenerative pathogenesis studies.
We also established oscillations in synaptic protein expression as well as C4b in the
hippocampus. Considering that C4b expression is antiphase to that of Nr1d1, it is possible that
the perfect storm of low Nr1d1 and high C4b expression enhances synaptic pruning at night. This
may result in fewer synapses being detected at our 11PM (ZT17) timepoint. Our results are
robust, since we confirmed the loss of synapses by using multiple presynaptic markers. Future
work could explore the expression of Sirpa/Cd47 over the course of the day.
Several studies have illustrated the complexity of the interplay between cellular rhythms
and sleep in regulating synapses in the brain. Robust circadian rhythms in synaptic protein
expression and phosphorylation have bene described which are sleep-dependent (Brüning et al.,
2019; Noya et al., 2019). Furthermore, chronic sleep deprivation has also been linked to
astrocytic synaptic phagocytosis and microglial activation (Bellesi et al., 2017). This suggests an
important role for sleep, which should be explored in future studies. Notably, RKO have subtle
alterations in sleep but show grossly normal circadian rhythms in activity and are not sleep
deprived (Mang et al., 2016). A study in the rat prefrontal cortex found that synaptic elimination
was higher at ZT0 (Choudhury et al., 2020). Since these studies were done in the prefrontal
cortex, they suggest potential brain region specific pruning patterns by time of day.
Heterogeneity in synaptic pruning has already been described, with areas such as the cerebellum
exhibiting greater microglial phagocytic capacity (Ayata et al., 2018). Future work will have to
explore the patterns in microglial phagocytosis across more brain regions.
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4.6 Supplemental Information

Figure 4.6.1. Evidence of T cells in the RKO mouse brain. Staining for DAPI, CD3 (For T
Cells) and Iba1 in the hippocampus of a 6mo RKO mouse.

Our analysis of the RKO hippocampus for proinflammatory cytokines showed an
increase in CCL2 (Fig 2.4.1), which has been shown to be a chemoattractant for T cells from the
periphery(Carr et al., 1994). As such, we investigated the presence of T cells in the brain.
Preliminary staining using CD3 confirms the presence of T cells in the hippocampus of RKO
mice (Fig 4.6.1). In regular aging, the process of “inflammaging” is characterized by the chronic
low-grade inflammation and an increase in the production of proinflammatory mediators
(Franceschi et al., 2000). Microglia in the aging brain have been shown to exhibit low-grade
activation (Conde and Streit, 2006). Microglia can also function as antigen presenting cells by
expressing MHC II during activation (Schetters et al., 2018). It is possible that the activated
microglia in the RKO mice are attracting T cells to the brain and activating them through the
formation of MHC-mediated immunological synapses (Dustin, 2014). However, future
experiments are required to characterize this finding furthers.
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α antagonism does not rescue tau pathology A. Experimental plan for
Figure 4.6.2 REV-ERBα
treatment of P301S mice with SR9009. B. Representative images of the AT8 stained
hippocampus from P301S mice treated with either vehicle or SR9009 as well as the associated
quantifications (N = 8/group). C. Representative 60X images of Iba1 and CD68 co-stained
99

hippocampus from P301S mice treated with either vehicle or SR9009 as well as the associated
quantifications (N = 8/group).

Given the number of failed Alzheimer’s drug that have targeted Aβ (Mehta et al., 2017).
There has been a recent push to target other aspects of the disease for therapeutic windows.
Some of these include Tau and microglial activation. Microglia play myriad roles in AD
pathology including, the regulation of tau propagation (Perea et al., 2018). Since we noted an
increase in microglial activation with REV-ERBα deletion, we investigated the use of SR9009 to
augment gliosis. In the experimental paradigm, we injected 7-month-old P301S mice
intraperitoneally with 100mg/kg of SR9009 for 6 weeks. All injections were done at ZT2 before
the target REV-ERBα protein expression levels peaks (Feng et al., 2011). 2 hours after the last
injection, mice were sacrificed and analyzed for phospho-tau using AT8 and microglial
activation using Iba1 and CD68. Interestingly, we observed no significant differences between
the treatment and control groups in the hippocampus. We assessed the hippocampus, because it
is one of the first structures to have tau pathology in the P301S mouse (Yoshiyama et al., 2007).
This surprising result could be because the low-level tau pathology was far too advanced when
we started treatment. SR9009 has been shown to cross the blood brain barrier in previous studies
(Solt et al., 2012). Other metrics of degeneration, such as brain volume, and misfolded tau are
also being investigated in the lab. Since the target is a transcriptional repressor, its removal may
have striking effects, but its activation may be less effective. This is potentially due to a
maximum repressive effect in physiology. Future work would have to explore this if SR9009 is
to be translated from the bench to treat neurodegeneration.
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Figure 4.6.3. Microglia Specific Deletion of REV-ERBα
α does not induce gliosis or
complement activation. A. Western blots for REV-ERBα protein in cortical tissues from WT or
RKO mice as well as primary cells made from WT or Nr1d1-Flox/Flox mice and treated with
either a GFP or Cre virus to knockout out REV-ERBα. B. Representative 40X images of GFAP,
Iba1 and C3 staining in the hippocampus of either 3 mo control (CXAB-Cre-) or mice with a
microglial specific deletion of REV-ERBα (CXAB+Cre+).
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Given the striking effects on microgliosis that we noted in the RKO mice (Fig 2.4.1), we
investigated whether knocking out REV-ERBα specifically in microglia could recapitulate the
phenotypes. To confirm that our floxed mouse was working, we first made primary astrocytes
from a Nr1d1fl/fl mouse and a WT littermate. After treatment with either a control (GFP) or Cre
virus, we noted significantly reduced levels of REV-ERBα protein (Fig 4.6.3A). We bred the
Nr1d1/2fl/fl mouse with a CX3CR1Cre mouse to generate a microglia specific deletion of REVERBα/β (CXAB+CRe+). We assessed this mouse for gliosis and complement activation by
staining for GFAP, Iba1 and C3. Unlike the whole-body REV-ERBα mouse, the CXAB+Cre+
mouse did not show gliosis or complement activation. The mice were assessed at 3 months of
age. This timepoint could be too early to observe gliosis. Longevity studies have shown that
lifespans of 15 months in mice (Réu et al., 2017) and the fractalkine (CX3CR1) receptor Cre has
been shown to have long term specificity in microglia (Goldmann et al., 2013). Therefore,
turnover is not an issue. Other potential explanations could pertain to the influence of the gut
microbiome on microglia function. Recently, it was shown that the REV-ERBα controlled gene
Nfil3 has profound effects on the gut microbiome (Wang et al., 2017). Signals from the gut
microbiome have also been shown to regulate microglial function and development (Erny et al.,
2015). Therefore, it is possible that a gut signal in the whole-body REV-ERBα knockout mice is
regulating this microglial activation. Future studies will investigate these possibilities.
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Figure 4.6.4. Complement expression in neural and glial cells in vitro. A. qPCR for
complement gene expression in primary microglia B. primary astrocytes and C. primary cortical
neurons D. Representative staining for GFAP, Iba1 and C4 in the hippocampus of a 6mo RKO
mouse.
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In whole brain tissue, we found that deletion of REV-ERBα led to increased complement
gene expression. Thus, we investigated complement gene expression in different primary cells
from the brain. In primary REV-ERBα knockout microglia, we observed increased expression of
C1q, C3 and C4b compared to WT microglia (Fig 4.6.4 A). Interestingly, we didn’t observe any
increased expression of complement genes in REV-ERBα knockout astrocytes compared to WT
ones (Fig 4.6.4B). This was unexpected because we noted significant upregulation of C3 protein
in the astrocytes from the hippocampus of RKO mice (Fig 3.4.3G). The astrocytes used in these
experiments are from the cortex, which could be a confound. Primary astrocytes may be
activated at baseline. Therefore, the changes in complement gene expression may have been
masked. Alternatively, complement activation could be a non-cell-autonomous process in REVERBα KO astrocytes. Microglia could play important roles here. In RKO primary neurons, we
observed increased expression of C1q and C4b compared to WT ones (Fig 4.6.4C). C3 was
below the detection limit in neurons. Interestingly, in the hippocampus of RKO mice C4 protein
did not colocalize with either microglia or astrocytes (Fig 4.6.4D). While the source of
complement in the RKO brain is unknown, these data suggest potential involvement of glia.
Other cell types, like oligodendrocytes, have been described to upregulate complement in the
context of disease (Zhou et al., 2020). Future experiments could explore the role of
oligodendrocytes in REV-ERBα mediated gliosis and neurodegeneration.
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Figure 4.6.5. An image analysis-based pipeline for assessing microglial activation by using
morphology. A. A distribution of the microglia in a 40X image taken from a CX3CR1-GFP
mouse hippocampus, sorted by the bounding box length C, which is the longest axis. B. A
distribution of the microglia in a 40X image taken from a CX3CR1-GFP mouse hippocampus,
sorted by the sphericity C. The fraction of microglia with a sphericity of greater than 0.5 in each
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image taken from the hippocampi of CX3CR1-GFP mice sacrificed at 4 timepoints D. The
fraction of microglia with a bounding box length c less than 15 in each image taken from the
hippocampi of CX3CR1-GFP mice sacrificed at 4 timepoints E. A representational graph of the
oscillation in microglial activation over the course of the day.

Homeostatic microglia rapidly respond to changes in the brain microenvironment in part
by changing morphology (Nayak et al., 2014). Activated microglia, generally are more spherical
and occupy a smaller volume in 3-dimensional space (Davis et al., 2017). Using the CX3CR1GFP mouse, which expresses green fluorescent protein in microglia (Jung et al., 2000), and the
Bitplane imaris software, we began to devise a high throughput method for assessing microglial
activation changes. In z-stacks collected by imaging coronal sections from the CX3CR1-GFP
mice, we built 3-D reconstructions that were representative of the microglial morphology. The
microglial 3-D reconstructions in each picture can be sorted by sphericity, which ranges from 01, and Bounding box object-oriented length C, which is the longest axis in an XYZ volume for
each microglia. Representative pictures of the reconstructions are shown in Fig 4.6.5 A and B.
Ramified, homeostatic microglia, which are less activated, will occupy more 3-D space and be
less spherical. Therefore, the bounding box object-oriented C values will be high, and the
sphericity will be low (closer to 0). Conversely, activated, amoeboid microglia will have lower
bounding box object-oriented C values and higher sphericity (closer to 1). Using this
classification system, we sorted the microglia in each picture and set thresholds for activation higher than 0.5 for sphericity and lower than 15 for bounding box object-oriented length C. In
both the CA3 and CA1 regions, we could show that microglial activation oscillated by time of
day (Fig 4.6.5C, D). The lowest level of microglial activation (as determined by the fraction with
bounding box object-oriented length C less than 15 and sphericity greater than 0.5) was observed
at 11AM and the highest fraction was observed at 5AM (Fig 4.6.5E). This is in agreement with
other results obtained from using Iba1 staining. While this approach uses an artificial threshold
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for sphericity and bounding box object-oriented length C, future approaches could plot a
distribution of all the microglial morphologies to determine changes in activation. These data
present a proof of concept for using image analysis to gain insights into biological function of
microglia in the brain. The rate-limiting step for this high throughput approach is the image
acquisition. However, as microscope technologies get better, this can evolve into a viable
approach for true high throughput analysis of microglial activation. Further validation can also
be done in mouse models that have more microglial activation such as AD or even in the RKO
mice.
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Chapter 5: Discussion, Conclusions and Future Directions
5.1 Perspective
The circadian clock has been described to play roles in a number of diseases. Since it is
fundamental to life on Earth, it is unsurprising that its dysfunction precedes or is associated with
disease sequalae. The emerging role of the circadian clock in neurodegenerative disease (Musiek
and Holtzman, 2016) represents opportunities to open new therapeutic windows.
Neurodegenerative diseases are on the rise in the aging population (Heemels, 2016). It is
undoubtedly one of the great challenges of this century and requires immediate attention.
In this thesis we address the influence of circadian clock proteins on microglial function
and synaptic health. Both of these are essential characteristics of neurodegenerative pathology
(Szepesi et al., 2018).With our newfound understanding of how the clock interacts with these
phenomena, we have begun to untangle an intricate web of interaction that is central to
neurodegeneration. We also begin to investigate therapeutic avenues to leverage the clock. Our
experiments bring to light the difficulty in targeting clock proteins to affect neurodegeneration.
We find that simply activating REV-ERBα is not enough to reverse pathology.
REV-ERBα is a nuclear hormone receptor that has expression in most tissues, but is
enriched in skeletal muscle and brain tissue (Mollema et al., 2011). In skeletal muscle, REVERBα has been shown to regulate important physiological processes such as oxidative capacity
and mitochondrial biogenesis (Woldt et al., 2013). However, the functions of REV-ERBα in the
brain have been poorly explored so far. REV-ERBα in the brain has been associated with the
organization of food intake (Sen et al., 2018), brain development (Goto et al., 2017) and orexin
gene expression (Amador et al., 2016).
In this thesis, we firmly establish REV-ERBα as the linchpin of multiple CNS processes,
including microglial activation, astrocyte activation and synaptic homeostasis (Fig 5.1).
Interestingly, these processes have been shown to interact independently with each other.
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Astrocytes and microglia can interact with each other via a number of mechanisms including
communications, synchrony and relay effects (Vainchtein and Molofsky, 2020). Astrocytes are
critical for synaptic transmission, plasticity, formation and even pruning (Chung et al., 2015).
Microglia prune synapses during development (Schafer et al., 2012) and in neuropsychiatric
disease such as epilepsy (Andoh et al., 2019), AD (Hong et al., 2016) and Schizophrenia
(Sellgren et al., 2019). With REV-ERBα controlling various aspects of these processes, there
may be multiple windows to affect CNS disease through the circadian clock.
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Figure 5.1 REV-ERBα
α regulates microglial, astrocytic and synaptic biology. A schematic
showing the complex interactions between the circadian clock protein REV-ERBα and various
brain processes.

5.2 REV-ERBα gates microglial activation
Chapter 2 of the thesis identifies intense microglial activation in the RKO mouse
hippocampus. Immunohistochemical staining using Iba1 showed gliosis throughout the
hippocampus, including the dentate gyrus and CA1-CA3. The immunohistochemical methods
were corroborated using qPCR quantification of proinflammatory messenger RNAs. These
include Trem2 and Il1b. Enhanced IL1-β signaling in microglia is linked to neuronal survival
through activation of the NLRP3 inflammasome (Todd et al., 2019). IL-1β signaling in microglia
can also be influenced by LPS (Lively and Schlichter, 2018).
In addition to their homeostatic functions, microglia have recently gained attention for
their potential causative role in neurodegenerative pathogenesis. Recent GWAS studies indicated
that mutations in microglial and phagocytosis genes are highly associated with increased
Alzheimer’s disease(AD) risk(Karch and Goate, 2015). One of those genes is Trem2, which we
found to be upregulated in the hippocampus of Rev-erbα KO mice. Of note, Trem2 is a damageassociated microglial gene which is upregulated in microglia surrounding amyloid
plaques(Keren-Shaul et al., 2017b). Deletion of Trem2 is known to impair microglial responses
to amyloid plaques and disrupt microglial synapse elimination.
REV-ERBα deletion is also associated with increased microglial phagocytic activation –
as seen by increased CD68/Iba1 colocalization in RKO microglia. Other work has also shown
that increases in microglial CD68 can result in increased synaptic pruning in the
hippocampus(Filipello et al., 2018). Furthermore, we noted morphological changes that are
associated with greater phagocytic capacity. RKO microglia showed less branching, which is
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indicative of greater activation and phagocytosis. These suggested to us that REV-ERBα in
microglia could potentially regulate synaptic elimination, perhaps through regulation of Trem2.
Although Aβ plaque and Tau tangle formation are the classical neuropathological hallmarks of
AD, decline in synaptic health has been found to be most closely correlated with cognitive
decline (Jack et al., 2013). Thus, deeper understanding of the processes that affect synaptic
health is critical. Given the increases phagocytic capacity of REV-ERBα KO microglia, it is
reasonable to hypothesize a decline in synaptic health in AD models lacking REV-ERBα.
However, the effects may not be so straightforward. Increases in microglial phagocytosis can
result in reduced Aβ burden in the brain(Lee and Landreth, 2010; Lee et al., 2020b), but can also
exacerbate Tau pathology(Maphis et al., 2015).
REV-ERBα deletion also induces the expression of Ccl2, which has profound effects on
T cell biology and maturation. CCL2 directs T cell recruitment into the brain in a CCR2
dependent manner (Cédile et al., 2017). We also noted the presence of T cells in the
hippocampus in RKO mice (shown in the Supplementary figures). Also, CCL2 enhances IL-4
expression, which in turn stimulates the T-cell receptor and leads to maturation (Deshmane et al.,
2009). Microglia-recruited T-cells influence neurodegenerative pathogenesis (Kipnis et al.,
2004). This has interesting implications for the role of REV-ERBα in neurodegeneration. In one
aspect, REV-ERBα seems to regulate microglial biology to promote neuronal damage. In
another, it enhances signaling that results in peripheral immune cell recruitment. Further studies
can investigate the effects of this infiltration.
Transcriptomic analyses of REV-ERBα KO brains revealed increases in NF-κB signaling
among others. GO Term analyses of also showed upregulation in biological process such as
immune system process, innate immune response and immune response in the RKO brain. Since
microglia are the primary immune cells of the brain that respond to danger signals (Norris and
Kipnis, 2019), we invested the immune signaling in them first. Primary microglia from RKO
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mouse brains had increased Il6 and Tnfa expression at baseline. RKO primary microglia also
showed enhanced NF-κB signaling at baseline and in response to LPS stimulation. Interestingly,
REV-ERBα protein physically bound to regulatory sequences in NF-κB signaling proteins such
as TRAF2 and NFKBIB. REV-ERBα is a dedicated transcriptional repressor (Chatterjee et al.,
2019). Therefore, loss of REV-ERBα results in aberrant NF-κB signaling through TRAF2, since
it is an activating factor in the NF-κB signaling cascade. TRAF2 overexpression enhances
neuronal damage in models of stroke (Li et al., 2019). Changes in TRAF2 could be a
contributing factor to the neuronal damage we observe in the RKO mice. However, further work
is required to firmly establish this link.

5.3 REV-ERBα regulates astrocyte activation in a non-cell autonomous
manner
In Chapter 2, we also found that knocking out REV-ERBα led to astrogliosis in the brain.
RKO mouse brains display astrogliosis by immunohistochemistry, western blot and qPCR
analysis. The upregulation in GFAP immunoreactivity was primarily in the hippocampus, where
GFAP+ astrocytes are found in abundance (Matias et al., 2019). We also noted an increase in
GFAP immunoreactivity in the retrosplenial cortex. In the mouse brain, GFAP does not get
significantly upregulated in RKO mice until about 4 months of age. In the RKO brain the
astrocytes display gene expression signatures consistent with the pan reactive phenotype
described in Liddelow et al (Liddelow et al., 2017). These reactive astrocytes could also
contribute to neuronal damage in the context of REV-ERBα deletion in the brain (Phatnani and
Maniatis, 2015). Isolated RKO astrocytes and astrocytes treated with siNr1d1 in culture were not
as activated as the isolated RKO microglia. While they did show an exacerbated response to LPS
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by expressing more Il1b and Il6, at baseline they did not show higher levels of other markers
such as Gfap and Serpina3n.
REV-ERBα deletion in isolated cultured microglia led to proinflammatory signaling,
while REV-ERBα knockdown did not induce Gfap expression in cultured astrocytes. This
suggests that REV-ERBα deletion may exert effects by driving microglial activation, which in
turn leads indirectly to astrocyte activation. This finding is in contrast to Bmal1 knockdown in
astrocytes, which induces cell-autonomous astrocyte activation (Lananna et al., 2018b),
suggesting that BMAL1 regulates astrocyte activation independently of Rev-erbα. While
astrocytes express RORα, which competes with REV-ERBα interaction with RORE sites in the
genome, microglia do not (Journiac et al., 2009), potentially allowing increased Rev-erbα
interaction with RORE sites in the genome (Papazyan et al., 2016) and maximizing its
transcriptional effect in microglia. Furthermore, our work shows that conditioned media (CM)
from REV-ERBα deficiency in mixed glial cultures (containing microglia) exacerbated neuronal
cell death in response to an injury stimulus, while CM from microglia-depleted astrocyte cultures
did not. These data suggest that REV-ERBα-deficiency drives neuroinflammation via a cell
autonomous effect on microglia. Microglia-astrocyte crosstalk in the brain is essential in both
normal brain homeostasis (Shinozaki et al., 2017) and neurodegeneration (Lian et al., 2016), and
activated microglia can induce neurotoxic activation in astrocytes (Liddelow et al., 2017). We
observed upregulation of several pan-reactive astrocyte transcripts in REV-ERBα KO
hippocampus, suggesting indirect astrocyte activation that may contribute to brain pathology.
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5.4 REV-ERBα activation limits the proinflammatory milieu but doesn’t
affect pathology
In the RKO mice, we also found that peripheral injection of the endotoxin LPS elicited an
exacerbated inflammatory response compared to WT littermates. Inflammatory markers such as
Gfap, Il6, Ccl2 and Hmox1 were all upregulated more than 2-fold in the brains of the RKO mice
compared to the WT littermates, given the same dose of LPS. Both microglia and astrocytes
express TLR4, the receptor that LPS binds to and signals through (Shen et al., 2016). TLR4
signaling can activate NF-κB and enhance the release of a proinflammatory milieu (Küper et al.,
2012). Since we showed that RKO microglia have enhanced NF-κB signaling through TRAF2
de-repression, it is unsurprising that we observe this enhanced proinflammatory milieu following
LPS injection. The drug SR9009 binds to both REV-ERBα and REV-ERBβ and activate them
(Stujanna et al., 2017). Pre-treatment of mice with SR9009 before an LPS treatment resulted in
reduced expression of proinflammatory mediators such as Il6 and Ccl2. In primary microglia
and astrocytes, we found that pre-treatment with SR9009 reduced levels of IL-1β release and Il6
release respectively. We tested the SR9009 in RKO microglia and astrocytes as well to confirm
specificity through REV-ERBα. Studies have shown that SR9009 can have non-REV-ERBmediated effects in liver cells (Dierickx et al., 2019). While the mechanisms of SR9009’s effects
on a cellular level are the subject of many labs, our experiments show that it can have effects
through REV-ERBα and these effects can limit the proinflammatory milieu. However, when we
treated P301S mice with SR9009 for six weeks, we didn’t observe any changes in tau pathology
or microglial activation.
While results from our group and others(Guo et al., 2018) are encouraging, there is a
considerable knowledge gap that must be addressed before attempting to predict the effect of
REV-ERB targeted drugs in neurodegenerative diseases. First, LPS-induced neuroinflammation
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is very different than the inflammation observed in neurodegenerative diseases. As an example,
TREM2 is suppressed by LPS, but is upregulated by amyloid plaque pathology. Second, simply
reducing neuroinflammation may not be enough to ameliorate neurodegenerative sequelae, as
glial activation can exert differing effects on various aspects of pathology at different points in
disease course. Using Alzheimer’s Disease as an example, inhibiting neuroinflammation through
REV-ERBα activation could abolish the early protective effects provided by increased
phagocytic capacity, as more phagocytic microglia could clear plaques and tangles more
efficiently and delay the onset of neurodegeneration. Recent work by Lee et al has shown that
REV-ERBα deletion can reduce amyloid plaque pathology in a 5XFAD model of AD (Lee et al.,
2020a). Conversely, REV-ERBα activation could provide protection from synapse loss later in
the disease course. Additionally, continuous activation/blockade of REV-ERBα could be
detrimental since our data shows that even microglial activation cycles by time of day, and these
cycles may be important for normal brain homeostasis. Finally, aged microglia are primed and
exhibit decreased phagocytosis and exaggerated responses to stimuli. Therefore, targeting
microglial REV-ERBα in aged animals or people would further comprise their ability to function
as phagocytes. This suggests that we would need to consider two axes of time when considering
using REV-ERBα – time of day and time course of the disease. To fully leverage REV-ERBα as
a therapeutic target in neurodegenerative disease all of the outlined factors have to be considered.
A summary of the ideas illustrated is in Figure 5.2.
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Figure 5.2. Considerations for the targeting of REV-ERBs in neurodegenerative diseases.
Hypothetical model showing the balance between modulating glial activation and altering
various aspects of neurodegenerative disease. As noted, activation of REV-ERBS could limit
glial activation, which might exert protective effects of synaptic health, but could exacerbate Aβ
and tau accumulation. The effects of REV-ERB may be modulated by circadian influence, as
well as stage of disease.

5.5 REV-ERBα regulates complement and synaptic health
Considering the effects of REV-ERBα on microglial and astrocytic activation, we
investigated the effects on neurons in Chapter 3. First, we used a culture system to interrogate
potential neuronal injury. Conditioned media from mixed glial that had REV-ERBα knocked
down were less capable of supporting neurons in the context of oxidative stress. Interestingly,
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when we depleted cultures of microglia, this effect went away. Once again pointing to the
necessity of microglia for REV-ERBα mediated neuronal injury. Despite these results, there are
some lingering questions. Is the lack of REV-ERBα in of itself neurotoxic or is this glia just less
supportive? Is the neurotoxicity mediated by factor released from microglia or does this factor
induce a reactive astrocyte phenotype that kills neurons? Future experiments need to identify the
potential factor(s) involved in neurotoxicity in vitro. In vivo, deletion of REV-ERBα induces
FABP7 expression, which is associated with increased neurogenesis (Schnell et al., 2014). These
effects were observed in the subgranular zone within the dentate gyrus of the hippocampus,
which is one of the few places in the adult brain that has active neurogenesis (Jin et al., 2001).
While the concept of neurogenesis in the adult brain was hotly debated in the past few years
(Boldrini et al., 2018; Sorrells et al., 2018), it is firmly established that neurogenesis occurs in
the adult brain.
Neuronal health is correlated with the synaptic connections (Bell and Hardingham, 2011).
Thus, we investigated the potential effects of REV-ERBα deletion on synapses in the
hippocampus. Both glia and neurons can contribute to complement expression in the brain,
which leads to synaptic engulfment and removal (Luchena et al., 2018). Therefore, we began our
experiments by looking at bulk transcriptomic data. In both the RKO mice and BMAL1
knockout mice, we found increases in complement genes such as C4b, C3, and C1q. Also, we
noted a decrease in Sirpa, which codes for the “do-not-eat-me” signal protein SIRPα.
Furthermore, RKO cortical tissue showed enhanced expression of C4b and C3. C3 protein was
also upregulated in both microglia and astrocytes in the RKO brain. C1q is the beginning factor
for the classical complement cascade (Reis et al., 2019) and has been shown in the brain to be
upregulated in neurodegenerative diseases where synapses are damaged (Morgan, 2018). Both
C3 and C4 have been found to be elevated in neuropsychiatric disorders (Druart and Le
Magueresse, 2019) and mediate synaptic engulfment (Sekar et al., 2016; Shi et al., 2015).
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These all pointed to a potential role of REV-ERBα in regulating synaptic pruning and
synaptic health itself. In our data, we found enhanced synaptic pruning in the RKO mice by both
EM and immunohistochemical methods. Associated with this synaptic pruning were stark
reductions in synaptic volume and number in the CA3 but not the CA1 region of the
hippocampus. The neuronal cell bodies in the dentate gyrus give rise to the synapses in the
molecular layer of the stratum lucidum of the CA3 (Bergmann et al., 2016). Therefore, we
examined the neurons in the dentate gyrus. These did not show signs of degeneration in the RKO
mouse brain. Our data suggest synapse specific effects of these circadian proteins. As to the
confinement of these effects to the CA3 region, further work needs to be done to fully
understand its significance. To understand network level effects of RKO deletion, we turned to
functional connectivity measurements by using optical intrinsic signal imaging (OISI).
Unlike other detection techniques, OISI offers a label-free, minimally invasive solution
for interrogating brain physiology. In OISI, hemoglobin is the main reporter because the
differences in absorption wavelengths of oxygenated versus de-oxygenated hemoglobin allow
for us to calculate changes in blood flow and therefore brain activity (Zepeda et al., 2004). Using
this technique, we found that areas in the brain associated with neurodegeneration (such as the
retrosplenial cortex) had reduced resting state functional connectivity. The mechanisms through
by which changes in synaptic structure can influence overall functional connectivity need to be
explored further. Overall, these changes in synapses are profound. Other studies have shown that
RKO mice have deficiencies in short-term, long-term and contextual memories as well
impairments in nest-building ability (Jager et al., 2014b). This effect was initially described as a
consequence of excessive dopamine signaling. In models of PD, dopamine oxidation has been
shown to be toxic to neurons (Zhang et al., 2019). REV-ERBα also protects against oxidative
stress (Sengupta et al., 2016). The combination of enhanced dopamine and enhanced oxidative
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stress in RKO mice could explain the potential effects on neurons in these mice. Future work
should investigate other brain regions for synaptic loss as well as neurodegeneration.

5.6 Time-of-day effects on microglial phagocytosis and synaptic health
Microglia in the CNs are highly dynamic and play myriad roles in maintaining brain
health and homeostasis(Gomez-Nicola and Perry, 2015). Despite their dynamic nature, previous
work has not examined potential influence of timing on microglial phagocytosis. In Chapter 4,
we found that microglia in the hippocampus have greater Iba1 volumes at 11PM compared to
11AM. REV-ERBα KO microglia do not show this difference in morphology at these 2 time
points. This hints at potential oscillation in microglial activation. To fully elucidate this
phenomenon, microglia need to be examined at more timepoints throughout the circadian day. 2
timepoints are not enough to fully characterize this. We began this effort in the supplementary
information by using imaris-based image analysis tools to assess microglial morphology over the
course of the day. We assessed 4 timepoints and found an oscillation with a trough at 11AM.
Other markers of activation, such as CD68 can also be analyzed at multiple timepoints. Finally,
microglia in RKO mice can also be analyzed at multiple timepoints as well as with other markers
of activation. The chosen timepoints could represent points in the cycle where the
morphologies/activation levels are the same. There could be potential shifts in phase or even
circadian reprogramming events (Sato et al., 2017).
Correlated with the timepoints of microglial activation were differences in synaptic
phagocytosis. We found that less synaptophysin volume was engulfed into CD68+ lysosomes by
microglia at 11AM versus 11PM in WT mice. In EM and viral injected approaches, microglia
recapitulated the time of day differences in engulfment. Interestingly, RKO mice did not show
this same time of day difference in synaptic engulfment. This points to a REV-ERBα as
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potentially controlling the oscillation in microglial phagocytosis. Oscillation in microglial
phagocytosis has important implications for CNS innate immunity. Similar to peripheral
macrophages (Kiessling et al., 2017), microglia may display differences in their response to
infection over the course of the day. Other work has already identified oscillations in the
inflammatory response by microglia (Fonken et al., 2015).
Interestingly, we also observed differences in synaptic protein expression and number
between 11AM and 11PM. At 11PM there was less synaptic volume and number in the CA3
region of the hippocampus. The 2 timepoints we checked had differences in C4b and Nr1d1
expression. This antiphase relationship between C4b and Nr1d1 could potential explain the
difference in synapses at the 2 timepoints. At 11AM, Nr1d1 expression is high and C4b
expression is low. Microglial activation and seemingly phagocytosis are regulated by REVERBα. At this timepoint microglia are less activated and prune less synapses. At 11PM, Nr1d1
expression is low and C4b is high. Thus, more synapses will be labeled in the context of
activated microglia. This will result in more synaptic pruning and therefore fewer synapses. This
shows coordination between two immune system components in the brain. Our data raises
interesting questions for CNS disease progression. First, does time of day influence brain disease
severity? Could we conflate effects by measuring at the wrong time of day? Also, how can we
leverage time of day effects to influence treatment of brain disease?

Conclusions & Future directions
Overall, we have established REV-ERBα and the circadian clock as potent regulators of
brain immune biology. Specifically, we note strong influences on microglial activation, astrocyte
activation and neuronal damage. Our work also demonstrates the complexity of targeting a
transcriptional repressor to influence disease. Despite having already made agonists and
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antagonists, simply activating REV-ERBα did not mitigate neuropathology. We also show that
REV-ERBα deletion abolishes time of day oscillations in microglial activation and synaptic
pruning. These data have important implications moving forward.
Future experiments need to consider how the peripheral immune system interacts with the
CNS immune system in RKO mice. We already began these investigations by demonstrating the
presence of T-cells in the brain in RKO mice. Additionally, other agonists and antagonists need
to be explored in modulating REV-ERBα to influence disease. A recent publication in Aging
Cell began that line of inquiry (Lee et al., 2020b). Future experiments also need to assess the
cell-type specificity of REV-ERBα mediated neuroinflammation. While it seems like the cell
autonomy comes from microglia, cell-type specific knockouts of REV-ERBα will be more
conclusive. We also begin to explore that in the supplemental experiments. More brain regions
need to be assessed for synaptic volume and synaptic pruning. We mostly investigated the
hippocampus, but future work can also look at the cortex as well as the cerebellum. Finally, more
timepoints need to be assessed for microglial activation and synaptic pruning in WT mice.
This work begins to explore the possibility of targeting the circadian clock to abrogate
neurodegenerative pathogenesis. While there is still a lot to be done, some key pieces of
information are needed moving forward. First, an optimization of dose time is critical. If the
target brain structures as well as the glial cells all display oscillatory biology, then pinpointing a
time of day to administer a drug will be helpful in treating disease. This process may require
more than just targeting the peak protein expression. Neurodegenerative disease is multifactorial,
and its etiology is poorly understood. However, I can envision the circadian clock as a target to
combat part of the etiology or stall the cascade of process that progress the disease. Small
molecules targeting REV-ERB and other circadian proteins could be administered at various
times of day to inhibit the expression of cytokines from glial cells that can damage synapses.
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Furthermore, whole body synchronization of the molecular circadian clock can also be
investigated.
In all these efforts, there needs to be a strong assessment of the potential side effects of
targeting the circadian clock. As with a lot of conserved biology, the circadian clock is
indispensable for the timing of myriad physiological processes. Drugs that alter this function
could inadvertently result in undesired side effects. Future work should consider targeting only
the cell types of interest while sparring other cells that are uninvolved in the disease pathogenesis
or progression. For example, a drug that targets microglia could have a targeting sequence that
localizes it to a TMEM119, CX3CR1 and HEXB positive cells only to provide some specificity.
If the pathogenic interaction between microglia and synapses is the target, then drugs can be
administered at night, when more synapses seem to be pruned. Due to the multifaceted nature of
neurodegenerative disease, I believe that these drugs will be most effective in abrogating
pathogenesis if administered early in the disease course. Subtle changes in the timing of
important brain processes need to be studied to tease out phenomena that can be open new
therapeutic windows.
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